BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pembrolizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pembrolizumab\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05852223-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05852223)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in High-risk Thy
 roid Cancer\nEstimated primary completion: November 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05852223
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545331-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06545331)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of XB010 in Subjects With Solid Tumors\nEstimated primary completion:
  23 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06545331
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955290-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02955290)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  CIMAvax Vaccine\, Nivolumab\, and Pembrolizumab in Treating Patients With
  Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer\nEst
 imated primary completion: 25 November 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02955290
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04046133-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04046133)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Phase 1b/II Trial of Pembroliz
 umab Plus IMRT in Stage III/IV Carcinoma of Anus\nEstimated primary comple
 tion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04046133
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05093231-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05093231)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab With Olaparib as
  Combined Therapy in Metastatic Pancreatic Cancer\nEstimated primary compl
 etion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05093231
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794645-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06794645)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Pemetrexed f
 or Progressive Chordoma\nEstimated primary completion: 30 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06794645
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02644369-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02644369)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of the 
 Effects of Pembrolizumab in Patients With Advanced Solid Tumors\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT02644369
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04209660-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04209660)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Lenvatinib and Pembrolizumab i
 n People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland C
 ancers\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04209660
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04417166-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04417166)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Radiotherapy
  for Patients With NK/T Cell Lymphoma\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4417166
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04520711-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04520711)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Hotspot TCR-T: A Phase I/Ib St
 udy of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR
 -T)\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04520711
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05047094-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase na readout est. (NCT05047094)
DESCRIPTION:Pembrolizumab\, phase na\, Head and Neck Squamous Cell Carcinom
 a.\nStudy: Alpha Radiation Emitters Device (DaRT) in Combination With Chec
 k Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05047094
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05082259-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05082259)
DESCRIPTION:Pembrolizumab\, phase 1\, Cervical Cancer.\nStudy: ASTEROID: A 
 Trial of ASTX660 in Combination With Pembrolizumab\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05082259
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05182164-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05182164)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Combination of Pembrolizumab a
 nd Cabozantinib in Patients With Advanced Sarcomas\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05182164
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319015-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05319015)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Neoadju
 vant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05319015
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05378425-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05378425)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of NTX-
 1088\, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR\, CD15
 5)\, as Monotherapy and Combined With Pembrolizumab\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05378425
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645380-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05645380)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant TI
 L- and Response-Adapted Chemoimmunotherapy for TNBC\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05645380
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745233-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase na readout est. (NCT05745233)
DESCRIPTION:Pembrolizumab\, phase na.\nStudy: Intraperitoneal Immune Checkp
 oint Inhibitor for Malignant Ascites\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 745233
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05784688-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05784688)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of
  TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Adv
 anced Solid Tumors\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05784688
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785754-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05785754)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: DCSZ11 as a Mon
 otherapy and in Combination in Patients With Advanced or Metastatic Solid 
 Tumors\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05785754
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05925491-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05925491)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in Locally Advan
 ced Sinonasal Carcinoma\nEstimated primary completion: December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05925491
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956041-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05956041)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Mogamulizuma
 b in Advanced-stage\, Relapsed/Refractory Cutaneous T-cell Lymphomas\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05956041
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05977907-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05977907)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcin
 oma of the Head and Neck (SCCHN).\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05977
 907
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06178445-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06178445)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: Efficac
 y and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously U
 ntreated HER2-positive Biliary Tract Cancer\nEstimated primary completion:
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06178445
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06211335-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06211335)
DESCRIPTION:Pembrolizumab\, phase 1\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Losartan\, Pembrolizumab and Stereotactic Body Radiation Therapy
  for the Treatment of Patients With Locally Recurrent\, Refractory or Olig
 ometastatic Head and Neck Squamous Cell Carcinoma\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06211335
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246110-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06246110)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in 
 Patients With Stage 4 NSCLC\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06246110
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580054-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06580054)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab for the Treatment of Locally Advanced and/or Recur
 rent Orbital or Periocular Cutaneous Squamous Cell Carcinoma\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06580054
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640283-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06640283)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Dynamic ctDN
 A Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and C
 linical Outcomes\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06640283
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in 
 Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative 
 Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell L
 ung Cancer\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03030378-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03030378)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Pembrolizumab a
 nd Recombinant Interleukin-12 in Treating Patients With Solid Tumors\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03030378
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420948-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05420948)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Pembrolizumab in Combination With Chemotherapy for He
 ad and Neck Cancer\nEstimated primary completion: 1 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05420948
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05491226-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05491226)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Reinvigorating
  TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Ra
 diation\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05491226
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161545-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06161545)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK 
 Cells for Resectable Head and Neck Squamous Cell Carcinoma\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06161545
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998069-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06998069)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Head and Neck Cancer Study Project in the Geriatric Population\n
 Estimated primary completion: 1 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06998069
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04421560-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04421560)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Pembrolizumab\, Ibrutinib an
 d Rituximab in PCNSL\nEstimated primary completion: 5 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04421560
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04164082-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04164082)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing
  the Addition of an Anti-cancer Drug\, Pembrolizumab\, to the Usual Intrav
 esical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unres
 ponsive Non-muscle Invasive Bladder Cancer\nEstimated primary completion: 
 9 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04164082
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879329-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04879329)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: A Study
  of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Tha
 t Expresses HER2\nEstimated primary completion: 11 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04879329
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669430-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05669430)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembro
 lizumab in Participants With Solid Tumor Malignancies\nEstimated primary c
 ompletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05669430
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05756569-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05756569)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Enfortumab Vedotin Plus Pembro
 lizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer
  of Variant Histology\nEstimated primary completion: 16 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05756569
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04185883)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Sotorasib Activ
 ity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (Code
 Break 101)\nEstimated primary completion: 17 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793761-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06793761)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Phase II Study to Evaluate the Efficacy and Safety of Salvage 
 Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy
  in Recurrent and Metastatic LPSCC/HPSCC\nEstimated primary completion: 20
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06793761
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05147558-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05147558)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of Pembrolizumab With 
 Lenvatinib in Women With Advanced Uterine Carcinosarcoma\nEstimated primar
 y completion: 23 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05147558
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05701527-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05701527)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of EBC-
 129 in Advanced Solid Tumours\nEstimated primary completion: 24 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT057015
 27
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03362060-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03362060)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: PVX-410 Vaccin
 e Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer\n
 Estimated primary completion: 30 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03362060
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03419481-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03419481)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Pem
 brolizumab in Hepatocellular Carcinoma\nEstimated primary completion: 30 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03419481
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04699123-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04699123)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 he Study of NC318 Alone or in Combination With Pembrolizumab in Patients W
 ith Advanced Non-small Cell Lung Cancer\nEstimated primary completion: 30 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04699123
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05041153-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05041153)
DESCRIPTION:Pembrolizumab\, phase 1\, Gastric Cancer.\nStudy: Pembrolizumab
  and Lenvatinib for the Treatment of Advanced\, Unresectable\, or Metastat
 ic Gastroesophageal Adenocarcinoma\nEstimated primary completion: 30 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5041153
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475235-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06475235)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Pembrolizumab + Chemotherapy i
 n Newly Diagnosed PCNSL\nEstimated primary completion: 30 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06475235
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03361852-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03361852)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Personalized Neoantigen Cancer
  Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03361852
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03383094-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03383094)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Chemoradiation vs Immunotherapy and Radiation for Head and Neck 
 Cancer\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03383094
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03712605-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03712605)
DESCRIPTION:Pembrolizumab\, phase 3\, Merkel Cell Carcinoma.\nStudy: Testin
 g Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma 
 After Surgery\, STAMP Trial\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03712605
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03804944-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03804944)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Converting HR+ Breast Cancer Into an Individualized Vaccine\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03804944
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04093167-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT04093167)
DESCRIPTION:Pembrolizumab\, phase 2/3.\nStudy: Study of CTDNA Response Adap
 tive Immuno-Chemotherapy in Lung Cancer\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04093167
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04265872-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04265872)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Bortezomib Fol
 lowed by Pembrolizumab and Cisplatin in metTNBC\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04265872
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04443088-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04443088)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: An Open-Label S
 tudy of INV-1120 as a Single Agent and in Combination With Pembrolizumab i
 n Adult Patients With Advanced Solid Tumors\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04443088
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04708418-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04708418)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: A Study Evaluating 
 Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Effica
 cy of Treatment in Patients With Operable Melanoma\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04708418
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04754321-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04754321)
DESCRIPTION:Pembrolizumab\, phase 1\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Rec
 urrent Head & Neck Cancer\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04754321
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180097-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05180097)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Brentuximab 
 Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Ly
 mphoma\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05180097
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05286437-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05286437)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast
  Cancer With Letrozole\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05286437
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05355051-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05355051)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Phase II Study of the Combin
 ation of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Ho
 dgkin's Lymphoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05355051
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05491083-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05491083)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Pembrolizumab
  and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05491083
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05496036-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05496036)
DESCRIPTION:Pembrolizumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Neoadj
 uvant PD-1 Blockade in Resectable Merkel Cell Carcinoma\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05496036
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514990-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05514990)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Bortezomib and Pembrolizumab
  With or Without Pelareorep for the Treatment of Relapsed or Refractory Mu
 ltiple Myeloma\, AMBUSH Trial\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055149
 90
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05675579-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05675579)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: A Phase II Stu
 dy of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immu
 nochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05675579
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05679921-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05679921)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pazopanib With or Without Pemb
 rolizumab for Metastatic Soft Tissue Sarcoma\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05679921
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06052839-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06052839)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metasta
 tic HNSCC\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06052839
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253494-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06253494)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Endometrial Cancer.\nStudy: Pembrol
 izumab\, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 
 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants Wit
 h Advanced or Metastatic Endometrial Cancer\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06253494
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324240-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06324240)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Personalized V
 accine Immunotherapy in Combination With Checkpoint Inhibitor for Treatmen
 t of Triple Negative Breast Cancer\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6324240
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06415487-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06415487)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: ACE2016 in Adul
 t Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epi
 dermal Growth Factor Receptor (EGFR)\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06415487
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06513624-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06513624)
DESCRIPTION:Pembrolizumab\, phase 1\, Ovarian Cancer.\nStudy: ETC-159 In Co
 mbination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06513624
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06907602-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06907602)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Esophageal Squamous Cell Carcinoma.
 \nStudy: Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Es
 ophageal Squamous Cell Carcinoma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 07602
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136545-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07136545)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: A Phase I/II Trial of HCB101 in Combination With Pembrolizumab
  for Patients With Platinum-Refractory\, Recurrent or Metastatic Head and 
 Neck Squamous Cell Carcinoma (SirH&N Trial)\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07136545
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162883-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07162883)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 harmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 162883
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02658279-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase na readout est. (NCT02658279)
DESCRIPTION:Pembrolizumab\, phase na.\nStudy: Pembrolizumab (MK-3475) in Pa
 tients With Recurrent Malignant Glioma With a Hypermutator Phenotype\nEsti
 mated primary completion: January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT02658279
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03313206-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03313206)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant Treatme
 nt Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patien
 ts With Resectable Head and Neck Mucosal Melanoma\nEstimated primary compl
 etion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03313206
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03546426-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03546426)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Pembrolizumab Plus Autologous 
 Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelio
 ma Who Have Failed Prior Therapies\nEstimated primary completion: January 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03546
 426
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04561362-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04561362)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignanci
 es\nEstimated primary completion: January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04561362
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04666740-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04666740)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of Pembrolizumab and O
 laparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Ho
 mologous Recombination Deficiency or Exceptional Treatment Response to Pla
 tinum-Based Therapy\nEstimated primary completion: January 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04666740
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683679-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04683679)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Study of Radiation Therapy With Pembrolizumab and Olaparib or Oth
 er Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor 
 Positive/Her2 Negative Breast Cancer\nEstimated primary completion: Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046
 83679
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05188508-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05188508)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab\, Olaparib\, and
  Temozolomide for People With Glioma\nEstimated primary completion: Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT051
 88508
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045195-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06045195)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in First-Line Tr
 eatment of Advanced-Stage Classical Hodgkin Lymphoma\nEstimated primary co
 mpletion: January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06045195
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03244384-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03244384)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Testing
  MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladd
 er Cancer and Locally Advanced Urothelial Cancer\nEstimated primary comple
 tion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03244384
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04134559-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04134559)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Che
 ckpoint Inhibition In Pediatric Hepatocellular Carcinoma\nEstimated primar
 y completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04134559
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05775471-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05775471)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radica
 l Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer\nEstimate
 d primary completion: 1 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05775471
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: D
 iclofenac for the Treatment of Patients With Metastatic Non-small Cell Lun
 g Cancer on Single Agent Immunotherapy\nEstimated primary completion: 1 Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06731270
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904573-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06904573)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Probiot
 ics in Advanced Urothelial Carcinoma\nEstimated primary completion: 1 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6904573
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05493566-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05493566)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: L
 ow-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-
 Small Cell Lung Cancer\nEstimated primary completion: 7 January 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05493566
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04616248-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270109
DTEND;VALUE=DATE:20270110
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04616248)
DESCRIPTION:Pembrolizumab\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: In Situ Immunomodulation With CDX-301\, Radiation Therapy\, CDX-114
 0 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors\nE
 stimated primary completion: 9 January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04616248
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04938609-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04938609)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC
 )\nEstimated primary completion: 11 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04938609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05609968)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan i
 n Combination With Pembrolizumab for Participants With Metastatic Non-smal
 l Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tum
 or Proportion Score (TPS) ≥50% (MK-3475-D46)\nEstimated primary completi
 on: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05609968
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05366166-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05366166)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab Plus Olaparib in LA-HNSCC\nEstimated primary compl
 etion: 21 January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05366166
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Disitam
 ab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urot
 helial Cancer Expressing HER2\nEstimated primary completion: 29 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0591129
 5
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246968-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06246968)
DESCRIPTION:Pembrolizumab\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy)
  in People With Breast Cancer\nEstimated primary completion: 29 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0624696
 8
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549946-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06549946)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: Ixovex-1 Single Agent and Combination Therapy\nEstimated prima
 ry completion: 30 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06549946
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376317-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07376317)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Optimization of Imm
 unotherapy Treatment for Advanced Melanoma in the Context of the Public Br
 azilian Health System (OTIMAS)\nEstimated primary completion: 30 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073763
 17
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04079166-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04079166)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: SCIB1 and iSCIB1+ i
 n Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pemb
 rolizumab (The SCOPE Study)\nEstimated primary completion: 31 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04079166
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04241185-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04241185)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Efficacy and Safety of Pembrol
 izumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Al
 one in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)\nEs
 timated primary completion: 31 January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04241185
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04712851-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04712851)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab for the Treatmen
 t of Cervical Intraepithelial Neoplasia\nEstimated primary completion: 31 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04712851
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05114421-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05114421)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Pembrolizumab
  and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients\nEstim
 ated primary completion: 31 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05114421
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406713-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05406713)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab in Muscle-invasive Bladder Cancer\nEstimated primary completion: 31
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05406713
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761951-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05761951)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Phase 2 S
 tudy Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor\
 , Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Rec
 urrent Endometrial Cancer\nEstimated primary completion: 31 January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05761951
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02287428-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT02287428)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Personalized NeoAntigen Cancer
  Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM\nEs
 timated primary completion: February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT02287428
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03832569-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03832569)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Study of Pembro
 lizumab Following Surgery in Patients With Microsatellite Instability High
  (MSI-H) Solid Tumors\nEstimated primary completion: February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03832569
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05382286)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Sacit
 uzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Ch
 oice and Pembrolizumab in Patients With Previously Untreated\, Locally Adv
 anced Inoperable or Metastatic Triple-Negative Breast Cancer\nEstimated pr
 imary completion: February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05382286
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228326-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06228326)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Maligna
 ncies Affecting the Lungs\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06228326
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03760575-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03760575)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Pembrolizumab in Combination W
 ith Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelio
 ma (MPM)\nEstimated primary completion: 1 February 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03760575
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724018-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04724018)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: Sacit
 uzumab Govitecan Plus EV in Metastatic UC\nEstimated primary completion: 1
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04724018
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03407144-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03407144)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Safety and Efficacy of Pembrol
 izumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymph
 oma (MK-3475-667/KEYNOTE-667)\nEstimated primary completion: 12 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT034071
 44
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492759-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06492759)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: High Dose Radi
 ation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Pat
 ients With PD-L1 Positive Metastatic Triple Negative Breast Cancer\nEstima
 ted primary completion: 12 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06492759
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03995147-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03995147)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Pembro
 lizumab in Combination With Chemotherapy for Patients With Untreated B Cel
 l Lymphoma\nEstimated primary completion: 20 February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03995147
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05036434-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05036434)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Phase II Trial of Pembrolizuma
 b Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma\nEstimated primar
 y completion: 28 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05036434
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05120596-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05120596)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: First in Huma
 n Study of T3P-Y058-739 (T3P)\nEstimated primary completion: 28 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT051205
 96
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180862-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07180862)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Partici
 pants\nEstimated primary completion: 28 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07180862
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784247-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04784247)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Lenvatinib and Pembrolizumab i
 n People With Advanced Soft Tissue Sarcoma\nEstimated primary completion: 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04784247
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04855435-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04855435)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Safety and Prel
 iminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tum
 ours\nEstimated primary completion: March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04855435
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05106127-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05106127)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Safety Le
 ad-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem\
 nEstimated primary completion: March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05106127
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05186974-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05186974)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Sacituzumab Govitecan Combinations in First-line Treatment of Part
 icipants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)\nE
 stimated primary completion: March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05186974
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271318-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05271318)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Oncolytic A
 denovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrol
 izumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatm
 ent for Ovarian Cancer.\nEstimated primary completion: March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05271318
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400160-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06400160)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Clinical Trial of TB511 in Advanced Solid Tumors\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06400160
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215637-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07215637)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Phase Ia/Ib Stu
 dy of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With
  Advanced or Metastatic Solid Tumors\nEstimated primary completion: March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07215
 637
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501650-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07501650)
DESCRIPTION:Pembrolizumab\, phase 1\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in 
 Head and Neck Cancer\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07501650
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05084430-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05084430)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Study of Pembrolizumab and M
 032 (NSC 733972)\nEstimated primary completion: 1 March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05084430
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06637306-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270310
DTEND;VALUE=DATE:20270311
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06637306)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Neoadjuvant Du
 pilumab\, Pembrolizumab\, Paclitaxel\, and Carboplatin in Locally Advanced
  Triple Negative Breast Cancer\nEstimated primary completion: 10 March 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06637306
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231122-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05231122)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Pembrolizumab
  Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for 
 the Treatment of Patients With Recurrent Ovarian Cancer\nEstimated primary
  completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05231122
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04976634-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04976634)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: Pembrolizumab P
 lus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016
 )\nEstimated primary completion: 22 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04976634
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Short-term Fasting Prior to PD
 -1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\n
 Estimated primary completion: 31 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04659811-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04659811)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Stereotactic Radiosurgery and 
 Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04659811
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04701476-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04701476)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 ATE and Pembrolizumab (MK3475) in mCRC and NSCLC\nEstimated primary comple
 tion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04701476
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05422794-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05422794)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Testing the Ad
 dition of Anti-Cancer Drug\, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pemb
 rolizumab)\, to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patien
 ts With Advanced Triple-Negative Breast Cancer\nEstimated primary completi
 on: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05422794
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422779-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase na readout est. (NCT07422779)
DESCRIPTION:Pembrolizumab\, phase na\, Melanoma.\nStudy: Immunotherapy Effi
 cacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Sloveni
 a\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07422779
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03153202-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03153202)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Study to Evaluate the Safety
  and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With 
 Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)\nEstimate
 d primary completion: April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03153202
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03504163-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03504163)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatme
 nt for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Gr
 ade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03504163
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04956640-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04956640)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (K
 RAS G12C)\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04956640
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270213-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05270213)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Evaluation of R
 BS2418 in Subjects With Advanced\, Metastatic Solid Tumors\nEstimated prim
 ary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05270213
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05410145-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05410145)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of D3
 S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid T
 umors With a KRAS p.G12C Mutation\nEstimated primary completion: April 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05410145
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377566-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06377566)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of BV-AVD in People Wi
 th Bulky Hodgkin Lymphoma\nEstimated primary completion: April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06377566
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940440-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06940440)
DESCRIPTION:Pembrolizumab\, phase 1\, Merkel Cell Carcinoma.\nStudy: IFx-Hu
 2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Me
 rkel Cell Carcinoma (MCC)\nEstimated primary completion: April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06940440
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255664-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07255664)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A FIH\, 
 Phase I/IIa\, Trial Assessing Feasibility of Administrations of TIL-based 
 Immunotherapy in Patients With Metastatic CRC and PC\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07255664
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04332874-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04332874)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of Pembrolizumab Plus 
 Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sa
 rcoma in the Arm or Leg\nEstimated primary completion: 1 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04332874
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468061-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04468061)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Sacituzumab Go
 vitecan +/- Pembrolizumab in Metastatic TNBC\nEstimated primary completion
 : 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04468061
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06407310-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06407310)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Pe
 mbrolizumab\, Carboplatin and Paclitaxel in Triple-negative Breast Cancer\
 nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06407310
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04317534-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04317534)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 djuvant Pembrolizumab vs Observation Following Curative Resection for Stag
 e I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm\
 nEstimated primary completion: 8 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04317534
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05349890-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05349890)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Personalized TCR-T: Study of A
 doptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)\nEst
 imated primary completion: 15 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05349890
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06493019-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06493019)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Study of Pembrolizumab\, Carbo
 platin\, Paclitaxel\, and Radiation for the Treatment of Early-Stage Anal 
 Cancer\nEstimated primary completion: 15 April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06493019
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06242834-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06242834)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Tazemetostat
  to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Pati
 ents With Aggressive B-Cell Non-Hodgkin's Lymphoma\nEstimated primary comp
 letion: 24 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06242834
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06364917)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: D
 ISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated primary 
 completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06364917
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02414269-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02414269)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Malignant Pleural Disease Treated With Autologous T Cells Genetic
 ally Engineered to Target the Cancer-Cell Surface Antigen Mesothelin\nEsti
 mated primary completion: 30 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT02414269
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03589339-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03589339)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: N
 BTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated
  With An Anti-PD-1 Therapy\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03589339
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04971499-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04971499)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Melanoma.\nStudy: A Study of Dapans
 utrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melano
 ma\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04971499
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05492682-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05492682)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: S
 TART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
 \nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05492682
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05537740-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05537740)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A First-in-huma
 n Study to Learn How Safe the Study Drug BAY3375968\, an Anti-CCR8 Antibod
 y\, is\, When Given Alone or in Combination With Pembrolizumab\, How it Af
 fects the Body\, How it Moves Into\, Through\, and Out of the Body\, and t
 o Find the Best Dose in Participants With Advanced Solid Tumors\nEstimated
  primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05537740
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06102395)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Evaluating the Efficacy and Safety of Pembrolizumab Plus Standar
 d Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC\n
 Estimated primary completion: 30 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06102395
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160335-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07160335)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase I Clinical Study to Evaluate the PK Profile\, Efficacy\, Safety and
  Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors\
 nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07160335
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05589818-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05589818)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab for Advanced NSCLC and PS 2-3\nEstimated primary completion: 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5589818
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05856981-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05856981)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tu
 mors\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05856981
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465069-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06465069)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of LY4052031 in Participants With Advanced or Metastatic Urothelial
  Cancer or Other Solid Tumors\nEstimated primary completion: May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06465069
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962787-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06962787)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of BL-B01D1+TKI±Pembr
 olizumab in Patients With Locally Advanced or Metastatic Renal Cancer\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06962787
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978114-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06978114)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: A Study
  of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Bili
 ary Tract Cancer\nEstimated primary completion: May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06978114
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054567-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07054567)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: A Study of B
 L-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metas
 tatic Cervical Cancer and Endometrial Cancer\nEstimated primary completion
 : May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07054567
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05358548-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05358548)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: ATATcH Alternating Treatment Plans for Advanced Cancer\nEstimate
 d primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05358548
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02628067-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02628067)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Study of Pem
 brolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-1
 58/KEYNOTE-158)\nEstimated primary completion: 4 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02628067
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study 
 of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressi
 ng Gastric Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0437
 9596
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04380636)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by P
 embrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Can
 cer (NSCLC) (MK-7339-012/KEYLYNK-012)\nEstimated primary completion: 5 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0438
 0636
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05132504-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270521
DTEND;VALUE=DATE:20270522
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05132504)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Neoadjuvant Folfirinox Combine
 d With Pembrolizumab Followed by Surgery for Patients With Resectable Panc
 reatic Cancer\nEstimated primary completion: 21 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05132504
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05440708-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05440708)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A
  Study of TTI-101 as Monotherapy and in Combination in Participants With L
 ocally Advanced or Metastatic\, and Unresectable Hepatocellular Carcinoma\
 nEstimated primary completion: 25 May 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05440708
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05173987-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05173987)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Study of Pembrolizumab (MK-347
 5) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Rec
 urrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
 \nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05173987
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05886439-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05886439)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: LK101 Combined With PD-1 or 
 PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer\nEstimated prima
 ry completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05886439
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02600949-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT02600949)
DESCRIPTION:Pembrolizumab\, phase 1\, Colorectal Cancer.\nStudy: Personaliz
 ed Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or
  Colorectal Cancer\nEstimated primary completion: 31 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02600949
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05085028-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05085028)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab 
 immuNothErapy for First-line Treatment of Patients With Advanced Non-small
  Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05085028
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563467-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05563467)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in the Treatment
  of Advanced\, Progressive Adrenocortical Carcinoma.\nEstimated primary co
 mpletion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05563467
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05766371-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05766371)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab Plus 177Lu-PSMA-
 617 in Patients With Castration Resistant Prostate Cancer\nEstimated prima
 ry completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05766371
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845814-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05845814)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Stu
 dy of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/
 - Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mU
 C) (MK-3475-04B/KEYMAKER-U04)\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05845814
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06004245-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06004245)
DESCRIPTION:Pembrolizumab\, phase 1\, Colorectal Cancer.\nStudy: A Study to
  Evaluate the Safety\, Pharmacokinetics\, and Anti-Tumor Activity of VVD-1
 33214 as Monotherapy and in Combination in Participants With Advanced Soli
 d Tumors\nEstimated primary completion: 31 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06004245
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159217-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07159217)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: Disitam
 ab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive 
 Advanced Biliary Tract Cancer\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07159217
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02886585-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02886585)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab In Central Nervo
 us System Metastases\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02886585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03179930-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03179930)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Combination Therapy With Entin
 ostat and Pembrolizumab in Relapsed and Refractory Lymphomas\nEstimated pr
 imary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03179930
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03546686-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03546686)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Peri-Operative
  Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negati
 ve Breast Cancer\nEstimated primary completion: June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03546686
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239624-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05239624)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin and Pembrolizumab in People With Bladder Cancer\nEstimated pri
 mary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05239624
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastat
 ic Solid Tumors\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05614739-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05614739)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: FORAGER-1: A Study of Vepugrat
 inib (LY3866288\; LOXO-435) in Participants With Cancer With a Change in a
  Gene Called FGFR3\nEstimated primary completion: June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05614739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05633654)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Sacit
 uzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Ch
 oice in Patients With Triple Negative Breast Cancer Who Have Residual Inva
 sive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 Optim
 ICE-RD/GBG 119/NSABP B-63)\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05633654
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732831-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05732831)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Safety and To
 lerability of TNG462 in Patients With MTAP-deleted Solid Tumors\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05732831
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733689-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05733689)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Response Adapted Neoadjuvant T
 herapy in Gastroesophageal Cancers (RANT-GC Trial)\nEstimated primary comp
 letion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05733689
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978102-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05978102)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Dose Escala
 tion and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanc
 ed Solid Tumors\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05978102
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353997-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06353997)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant IN
 BRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06353997
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906822-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06906822)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: PLUG-IN: Pembrolizu
 mab Combined With Enfortumab Vedotin for Advanced Melanoma Patients\nEstim
 ated primary completion: June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06906822
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484022-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07484022)
DESCRIPTION:Pembrolizumab\, phase 1\, Urothelial Carcinoma.\nStudy: Study o
 f GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelia
 l Cancer\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07484022
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04485013-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04485013)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: TTX-080 HLA-G Antagonist in Su
 bjects With Advanced Cancers\nEstimated primary completion: 1 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04485013
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05777603-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05777603)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Ce
 ll Lung Cancer\nEstimated primary completion: 1 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05777603
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439836-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06439836)
DESCRIPTION:Pembrolizumab\, phase 1\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab Plus CA-4948 for the Treatment of Patients With Progressive Metasta
 tic Urothelial Cancer Despite Prior Immunotherapy\nEstimated primary compl
 etion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06439836
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06576037-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06576037)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Phase Ib Study 
 of CBP-1019 in Combination With FOLFOX +/- Bevacizumab\, Pembrolizumab\, o
 r Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithel
 ial Origin\nEstimated primary completion: 1 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06576037
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332351-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07332351)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Neoadju
 vant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pem
 brolizumab for the Treatment of Muscle Invasive Bladder Cancer\, TRIFECTA 
 Trial\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07332351
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412054-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07412054)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Len
 vatinib and Pembrolizumab With or Without BCAA in Unresectable HCC\nEstima
 ted primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07412054
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06912087-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270605
DTEND;VALUE=DATE:20270606
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06912087)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Dose Finding Study of Zanzalin
 tinib With Pembrolizumab and Cetuximab in Head and Neck SCC\nEstimated pri
 mary completion: 5 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06912087
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934448-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05934448)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Pembro
  Plus CAR T-cell Therapy in R/R in PMBCL\nEstimated primary completion: 6 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05934448
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319730-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05319730)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Esophageal Squamous Cell Carcinoma.
 \nStudy: A Study to Evaluate Investigational Agents With or Without Pembro
 lizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previous
 ly Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Deat
 h Ligand 1 (PD-L1) Treatment (MK-3475-06B)\nEstimated primary completion: 
 11 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05319730
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04389632-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04389632)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Sigvotatug Vedotin in Advanced Solid Tumors\nEstimated primary c
 ompletion: 16 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04389632
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03505320-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03505320)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Zo
 lbetuximab (IMAB362) in Adults With Gastric Cancer\nEstimated primary comp
 letion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03505320
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03854474-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03854474)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: Testi
 ng the Addition of Tazemetostat to the Immunotherapy Drug\, Pembrolizumab 
 (MK-3475)\, in Advanced Urothelial Carcinoma\nEstimated primary completion
 : 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03854474
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030506-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05030506)
DESCRIPTION:Pembrolizumab\, phase 1\, Renal Cell Carcinoma.\nStudy: A Study
  of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib
  (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Particip
 ants With Advanced Renal Cell Carcinoma (MK-6482-010)\nEstimated primary c
 ompletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05030506
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034536-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05034536)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: PD-1 Antibody Thera
 py + Infliximab for Metastatic Melanoma\nEstimated primary completion: 30 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05034536
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096663-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT05096663)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] P
 lus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell
  Lung Cancer (A Lung-MAP Treatment Trial)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05096663
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05405595-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05405595)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: ADG126 in Com
 bination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tum
 ors\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05405595
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634875-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06634875)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Isunakinra
  Alone and in Combination With Pembrolizumab in Patients With Colorectal C
 ancer (MSS)\nEstimated primary completion: 30 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06634875
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Study of JSKN016 Combination Therapy in Inoperable Locally Advanc
 ed or Metastatic HER2-Negative Breast Cancer\nEstimated primary completion
 : 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06942234
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03220477-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03220477)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Pembrolizumab (Immunotherapy D
 rug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs)
  for Patients With Advanced Lung Cancer.\nEstimated primary completion: Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 220477
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03546582-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03546582)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurre
 nt or Second Primary Head and Neck Carcinoma\nEstimated primary completion
 : July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03546582
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03829254-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03829254)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Safety\, Ph
 armacokinetic and Clinical Activity Study of NUC-7738 in Patients With Adv
 anced Solid Tumours and Lymphoma\nEstimated primary completion: July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03829254
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04427293-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04427293)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Preoperative L
 envatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer 
 (TNBC)\nEstimated primary completion: July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04427293
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04960618-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04960618)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in Combination W
 ith Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndr
 ome\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04960618
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524935-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05524935)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Olaparib in Combina
 tion With Pembrolizumab for Advanced Uveal Melanoma\nEstimated primary com
 pletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05524935
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623319-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05623319)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Olaparib Tre
 atment of Extensive Small Cell Lung Cancer (ES-SCLC)\nEstimated primary co
 mpletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05623319
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970497-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05970497)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study Asses
 sing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumor
 s\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05970497
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188246-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07188246)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant\, 
 SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy
  in Breast Cancer\nEstimated primary completion: July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07188246
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591597-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07591597)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Multic
 enter\, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of 
 Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 P
 lus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal C
 ancer\nEstimated primary completion: July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07591597
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05570825-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05570825)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 X-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stag
 e IIIC or IV Non-Small Cell Lung Cancer\nEstimated primary completion: 1 J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5570825
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Pembrolizumab\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and 
 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician'
 s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or M
 etastatic Breast Cancer (MK-2870-010)\nEstimated primary completion: 11 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 312176
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843550-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270713
DTEND;VALUE=DATE:20270714
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07843550)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Phase 1/2 T
 rial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Prev
 iously Treated With Immune Checkpoint Inhibitor Monotherapy\nEstimated pri
 mary completion: 13 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07843550
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205706-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06205706)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  BI-1910 as a Single Agent and in Combination With Pembrolizumab for the T
 reatment of Advanced Solid Tumors\nEstimated primary completion: 14 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062057
 06
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187778-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270719
DTEND;VALUE=DATE:20270720
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07187778)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Phase I
 I Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as 
 Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)\nEstimated 
 primary completion: 19 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07187778
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384015-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05384015)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Study of Pembrolizumab\, Lenva
 tinib and Chemotherapy Combination in First Line Extensive-stage Small Cel
 l Lung Cancer\nEstimated primary completion: 30 July 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05384015
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05507541-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05507541)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: TTI-62
 2 in Combination With Pembrolizumab for the Treatment of Relapsed or Refra
 ctory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 30 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0550
 7541
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05878691-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05878691)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of GRC 
 54276 in Participants With Advanced Solid Tumors and Lymphomas.\nEstimated
  primary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05878691
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635824-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06635824)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 rial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Ove
 r Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC
 -06)\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06635824
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03219450-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03219450)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: A Personalized Neoantigen Canc
 er Vaccine in Treatment Naïve\, Asymptomatic Patients With IGHV Unmutated
  CLL.\nEstimated primary completion: 31 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03219450
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05967182-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05967182)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Single-Arm Study of Pembroli
 zumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentia
 lly Resectable Intrahepatic Cholangiocarcinoma\nEstimated primary completi
 on: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05967182
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011823-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07011823)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Immune-checkpoint Blockade Aft
 er Partial Breast Irradiation by Pembrolizumab in Early TNBC\nEstimated pr
 imary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07011823
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061964-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07061964)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Combini
 ng Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Remo
 val After Treatment Shrinks Muscle Invasive Bladder Cancer\, BRIGHT Trial\
 nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07061964
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03618550-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03618550)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Phase II Study of Second- Line
  Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma\nEstim
 ated primary completion: August 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03618550
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05020860-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05020860)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Correlation of
  Clinical Response to Pathologic Response in Patients With Early Breast Ca
 ncer\nEstimated primary completion: August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05020860
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alo
 ne or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or 
 Other Anticancer Therapies in Adult Participants With Locally Advanced or 
 Metastatic Solid Tumor Malignancies\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05081
 609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462496-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05462496)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Modulation of the Gut Microbio
 me With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Canc
 er\nEstimated primary completion: August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05462496
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05901285-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05901285)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Phase 1 Study o
 f Intratumoral Administration of VAX014 With Expansion in Combination With
  a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors\nEstimated 
 primary completion: August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05901285
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06027268-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06027268)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Phase II Trial
  of Trilaciclib\, Pembrolizumab\, Gemcitabine and Carboplatin in Metastati
 c Triple-Negative Breast Cancer\nEstimated primary completion: August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06027268
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06057038-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06057038)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Safety Trial 
 of GEN1042 in Japanese Subjects With Malignant Solid Tumors\nEstimated pri
 mary completion: August 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06057038
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06116136-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06116136)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Gastric Cancer.\nStudy: A Study to 
 Evaluate the Safety and the Activity of S095029 as Part of Combination The
 rapy in Advanced Gastroesophageal Junction/Gastric Cancers.\nEstimated pri
 mary completion: August 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06116136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06234397-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06234397)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Dose Escalation
  and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or 
 Metastatic Solid Tumors\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06234397
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917079-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06917079)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: B
 BO-11818 in Adult Subjects With KRAS Mutant Cancer\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06917079
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03603223-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03603223)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in Treating Part
 icipants With Leukoplakia\nEstimated primary completion: 1 August 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03603223
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894889-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05894889)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC\nEstimated pri
 mary completion: 1 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05894889
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545682-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06545682)
DESCRIPTION:Pembrolizumab\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEt
 astatic Breast caNcer or melanomA (SELENA)\nEstimated primary completion: 
 3 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06545682
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880549-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06880549)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of mRNA
 -4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer A
 gents in Participants With Solid Tumors\nEstimated primary completion: 3 A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06880549
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04069273-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270811
DTEND;VALUE=DATE:20270812
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04069273)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Novel SEQUEnc
 ed Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastr
 oesophageaL Adenocarcinoma\nEstimated primary completion: 11 August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04069273
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486817-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07486817)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: B
 eamion 44: A Study to Test How Well Zongertinib is Tolerated by People Wit
 h Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Co
 mbination With Chemotherapy With or Without Pembrolizumab\nEstimated prima
 ry completion: 12 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07486817
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438329-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270813
DTEND;VALUE=DATE:20270814
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438329)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: First-in-huma
 n Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors\nEstimated 
 primary completion: 13 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05438329
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05205109-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05205109)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study to Asse
 ss the Safety\, Pharmacokinetics\, Pharmacodynamics\, and Preliminary Effi
 cacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in 
 Patients With Advanced Solid Tumors\nEstimated primary completion: 30 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 205109
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951399-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06951399)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 racking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanc
 ed Non-Small Cell Lung Cancer\nEstimated primary completion: 30 August 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06951399
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04171622-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04171622)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Lenvatinib and Pembrolizumab f
 or the Treatment of Stage IVB Locally Advanced and Unresectable or Stage I
 VC Metastatic Anaplastic Thyroid Cancer\nEstimated primary completion: 31 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04171622
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05838768-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05838768)
DESCRIPTION:Pembrolizumab\, phase 1\, Colorectal Cancer.\nStudy: Study of H
 RO761 Alone or in Combination in Cancer Patients With Specific DNA Alterat
 ions Called Microsatellite Instability or Mismatch Repair Deficiency.\nEst
 imated primary completion: 31 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05838768
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806852-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06806852)
DESCRIPTION:Pembrolizumab\, phase 1\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study to Test Whether Treatment With BI 770371 in Combination 
 With Pembrolizumab With or Without Cetuximab Helps People With Head and Ne
 ck Cancer Compared With Pembrolizumab Alone\nEstimated primary completion:
  31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06806852
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: The Drug Rediscovery Protocol 
 (DRUP Trial)\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082439-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07082439)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Odetiglucan 
 in Liver Predominant Metastatic Colorectal Adenocarcinoma\nEstimated prima
 ry completion: September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07082439
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853690-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase na readout est. (NCT07853690)
DESCRIPTION:Pembrolizumab\, phase na\, Biliary Tract Cancer.\nStudy: Histot
 ripsy in Biliary Tract Cancer\nEstimated primary completion: September 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07853690
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 ilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Ce
 ll Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated primar
 y completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366347-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06366347)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: ALPINE: M
 aintenance Letrozole/Abemaciclib\nEstimated primary completion: 1 Septembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 66347
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377540-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06377540)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: MT2022-60: Ph 2 Study of Pembr
 o+ BEAM With ASCT for Relapsed Hodgkin Lymphoma\nEstimated primary complet
 ion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06377540
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514898-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06514898)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Adoptive T Cell Therapy\, DC V
 accines\, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blo
 ckade in Patients With Medulloblastoma\nEstimated primary completion: 1 Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06514898
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629700-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pembrolizumab: Phase na readout est. (NCT07629700)
DESCRIPTION:Pembrolizumab\, phase na\, Urothelial Carcinoma.\nStudy: Study 
 of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treat
 ed With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (EN
 DEAVOR)\nEstimated primary completion: 1 September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07629700
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793179-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03793179)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 esting the Timing of Pembrolizumab Alone or With Chemotherapy as First Lin
 e Treatment and Maintenance in Non-small Cell Lung Cancer\nEstimated prima
 ry completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03793179
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04697576-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04697576)
DESCRIPTION:Pembrolizumab\, phase 1\, Melanoma.\nStudy: Intralesional Influ
 enza Vaccine for the Treatment of Stage I-IV Melanoma\nEstimated primary c
 ompletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04697576
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05746897-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05746897)
DESCRIPTION:Pembrolizumab\, phase 1\, Ovarian Cancer.\nStudy: A First-in-hu
 man\, Phase I\, Open-label\, Multicenter Study of NM1F(Anti-PVRIG) in Pati
 ents With Advanced Solid Tumors\nEstimated primary completion: 30 Septembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT057
 46897
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05799144-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05799144)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: pBI-11 & TA-HPV (With Pembroli
 zumab as Treatment for Patients w/Advanced\, PD-L1 CPS≥1\, hrHPV+ Oropha
 ryngeal Cancer\nEstimated primary completion: 30 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05799144
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083844-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06083844)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Phase II Inve
 stigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclop
 hosphamide in Patients With High Grade Ovarian Cancer and Surgically Docum
 ented Minimal Residual Disease After Frontline Therapy\nEstimated primary 
 completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06083844
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06318897-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06318897)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Open-label\, S
 ingle Center\, Single-arm\, Phase 2 Study of Neoadjuvant Pembrolizumab in 
 Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-
 T1cN0M0 Triple Negative Breast Cancer\nEstimated primary completion: 30 Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06318897
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06600321-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06600321)
DESCRIPTION:Pembrolizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: A S
 tudy to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma\nEstim
 ated primary completion: 30 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06600321
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07327229-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07327229)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: A Phase Ib/II Study of ATG-0
 22 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claud
 in (CLDN) 18.2-positive\, HER2-negative\, Unresectable or Metastatic Gastr
 ic or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic G
 astric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07327229
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04946370-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04946370)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Phase I/II Trial of Pembroli
 zumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progr
 essive Metastatic Castration Resistant Prostate Cancer\nEstimated primary 
 completion: October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04946370
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06302569-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06302569)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab Plus Enfortumab 
 Vedotin in Collecting Duct and Renal Medullary Carcinoma\nEstimated primar
 y completion: October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06302569
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561685-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06561685)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumo
 rs\nEstimated primary completion: October 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06561685
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207395-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07207395)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Orally Administered JBI-802 Alone or in Combination With Pembrol
 izumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation
 .\nEstimated primary completion: October 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07207395
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07267338-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07267338)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab + MRGOO3 as Neoa
 djuvant in NPC\nEstimated primary completion: October 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07267338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041503-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06041503)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Enfortumab Vedotin With or Wit
 hout Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)\nEstimated prim
 ary completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06041503
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174453-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07174453)
DESCRIPTION:Pembrolizumab\, phase 3\, Solid Tumors.\nStudy: Trial to Evalua
 te irAEs With Different Standard of Care Dosing Strategies of Standard of 
 Care Immunotherapies\nEstimated primary completion: 1 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07174453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05404945-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271003
DTEND;VALUE=DATE:20271004
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05404945)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Fitness-adapted\, Pembrolizuma
 b-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years
  of Age and Above\nEstimated primary completion: 3 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05404945
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05544929-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271005
DTEND;VALUE=DATE:20271006
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05544929)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizu
 mab in Patients With Select Advanced Cancers\nEstimated primary completion
 : 5 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05544929
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06232564-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06232564)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of Etoposide-carboplat
 in in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
 \nEstimated primary completion: 15 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06232564
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06845319-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06845319)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: NeoCARD: Anthr
 acycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Can
 cer Patients\nEstimated primary completion: 20 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06845319
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Study of Pembrolizumab (MK-3
 475) Combination Therapies in Metastatic Castration-Resistant Prostate Can
 cer (MK-3475-365/KEYNOTE-365)\nEstimated primary completion: 22 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0286157
 3
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624204-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04624204)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Placebo-controlled\, Study of 
 Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembroliz
 umab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small 
 Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)\nEstimated primary co
 mpletion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04624204
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05903833-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05903833)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab Combination With
  Lenvatinib in Pts With Recurrent\,Persistent\,Metastatic or Locally Advan
 ced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy\nEstima
 ted primary completion: 30 October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05903833
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922904-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05922904)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: PET Adapted Brentuximab Vedoti
 n and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Cla
 ssic Hodgkin Lymphoma\nEstimated primary completion: 30 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05922904
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929235-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05929235)
DESCRIPTION:Pembrolizumab\, phase 1\, Urothelial Carcinoma.\nStudy: A Study
  of FX-909 in Patients With Advanced Solid Malignancies\, Including Advanc
 ed Urothelial Carcinoma\nEstimated primary completion: 30 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05929235
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04429542-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04429542)
DESCRIPTION:Pembrolizumab\, phase 1\, Ovarian Cancer.\nStudy: Study of Safe
 ty and Tolerability of BCA101 Monotherapy and in Combination Therapy in Pa
 tients With EGFR-driven Advanced Solid Tumors\nEstimated primary completio
 n: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04429542
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907980-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05907980)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Phase I Study
  of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patien
 ts With Solid Tumors\nEstimated primary completion: 31 October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05907980
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04219254-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04219254)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of BI
 -1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tu
 mors\nEstimated primary completion: November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04219254
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisot
 uzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor i
 n Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With N
 o Prior Treatment for Advanced Disease\, and No Actionable Genomic Alterat
 ions\nEstimated primary completion: November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809140-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06809140)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatmen
 t of Muscle-invasive Bladder Cancer\nEstimated primary completion: Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 09140
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276880-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07276880)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Preoperative C
 hemotherapy\, Pembrolizumab and Low or High Dose RADiation in an Expansion
  Cohort of Node(+)\, Triple Negative Breast Cancer\nEstimated primary comp
 letion: November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07276880
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667167-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06667167)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irst Line Therapy for Extensive SCLC Patients\, Treated with Chemo+Keytrud
 a Followed by Keytuda+Trodelvy\nEstimated primary completion: 1 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066671
 67
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03313778-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271121
DTEND;VALUE=DATE:20271122
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03313778)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Safety\, Tolera
 bility\, and Immunogenicity of mRNA-4157 Alone and in Combination in Parti
 cipants With Solid Tumors\nEstimated primary completion: 21 November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03313778
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04297605-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04297605)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab and Single Agent Chemotherapy as First Line Treatmen
 t for Patients With Locally Advanced or Metastatic Non-small Cell Lung Can
 cer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
 \nEstimated primary completion: 30 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04297605
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642780-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05642780)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: SKB264 in Combi
 nation With Pembrolizumab in Subjects With Selected Solid Tumors\nEstimate
 d primary completion: 30 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05642780
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06108050-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06108050)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: JZP898 Intraven
 ous Infusion as Monotherapy and Combination With Pembrolizumab in Adults W
 ith Advanced/Metastatic Solid Tumors\nEstimated primary completion: 30 Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06108050
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123338-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06123338)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Pe
 mbrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastr
 ic Cancer\nEstimated primary completion: 30 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06123338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06142617-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06142617)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSC
 LC Patients With EGFR Exon 21 Point Mutation.\nEstimated primary completio
 n: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06142617
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994806-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06994806)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study to Inve
 stigate the Safety and Efficacy of KQB168 as Monotherapy and in Combinatio
 n in Participants With Advanced Solid Malignancies\nEstimated primary comp
 letion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06994806
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261683-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07261683)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Phase II Stud
 y of Weekly Paclitaxel/Nab-Paclitaxel\, Pembrolizumab\, and Mirabegron for
  Recurrent Ovarian Cancer\nEstimated primary completion: 30 November 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07261683
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455032-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07455032)
DESCRIPTION:Pembrolizumab\, phase 1\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgic
 ally Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas\nE
 stimated primary completion: 30 November 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07455032
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475806-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07475806)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study to Find Out if Enfortu
 mab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bla
 dder Cancer Keep Their Bladder\nEstimated primary completion: 30 November 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07475
 806
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03283137-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03283137)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Combination of Pembrolizumab W
 ith TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03283137
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556228-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03556228)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA O
 verexpression Driven Solid Tumors or Lymphoma\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03556228
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04150640-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04150640)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Oxaliplatin and Liposomal Irin
 otecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal
  and Gastric Adenocarcinoma\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04150640
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04645602-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04645602)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Merck IIT: RRP Pembro and Lenv
 atinib\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04645602
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04865887-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04865887)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Pembrolizuma
 b and Lenvatinib in Advanced Cervical Cancer\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04865887
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977375-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04977375)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Trial of Anti-PD-1 Immunothe
 rapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04977375
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05077215-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05077215)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: Efficacy 
 and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem i
 n Advanced Endometrial Cancer\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05077215
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 mA
 b\, Administered Alone and in Combination With a PD-1 Inhibitor or Chemoth
 erapy (the MORNINGSTAR Study)\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05431270
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482893-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05482893)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Spevatam
 ig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted The
 rapy and/or ICI\, for the Treatment of Patients With Advanced Gastrointest
 inal Cancers\, Including Gastric\, Gastroesophageal Junction\, Pancreatic 
 Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05482893
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05547321-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05547321)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Efficacy and Sa
 fety Study of OMTX705\, Monotherapy and Anti-PD-1-combined\, in Subjects W
 ith Advanced Solid Tumors.\nEstimated primary completion: December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05547321
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06086288-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06086288)
DESCRIPTION:Pembrolizumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Study 
 of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in T
 reatment naïve Advanced meRkel Cell cArcinoma (MCC)\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06086288
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646445-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06646445)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Neoadjuvant Pembrolizumab With
  a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES
  Study.\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06646445
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06694350-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06694350)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab in Combination with Flutamide Treatment for Recurr
 ence / Metastasis HNSCC\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06694350
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771544-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06771544)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Metronomic Cyclopho
 sphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06771544
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227168-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07227168)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07227168
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264816-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07264816)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unre
 sectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous N
 SCLC\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07264816
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343596-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase na readout est. (NCT07343596)
DESCRIPTION:Pembrolizumab\, phase na.\nStudy: Study to Identify Biomarkers 
 of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Defin
 itive Surgery\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07343596
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565285-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07565285)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: The Efficacy and Sa
 fety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Me
 lanoma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07565285
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027124-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07027124)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Neoadjuvant ADT + Darolutamide
  With Pembrolizumab\, Followed by Adjuvant Pembrolizumab in Molecularly St
 ratified High-Risk Prostate Cancer\nEstimated primary completion: 1 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 027124
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05568550-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05568550)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembro With Radiation With or 
 Without Olaparib\nEstimated primary completion: 2 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05568550
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158918-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07158918)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: ABL103 in Com
 bination With Pembrolizumab\, With or Without Taxane in Advanced or Metast
 atic Solid Tumors\nEstimated primary completion: 2 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07158918
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06795412-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06795412)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Phase 1/2 Stu
 dy of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors\n
 Estimated primary completion: 6 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06795412
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006013-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271216
DTEND;VALUE=DATE:20271217
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06006013)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Cabozantinib in Combination Wi
 th Pembrolizumab for the Treatment of Patients With Locally Advanced\, Met
 astatic\, or Unresectable Adrenal Cortical Cancer\nEstimated primary compl
 etion: 16 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06006013
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06502743-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06502743)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: First-lin
 e Carboplatin and Paclitaxel in Combination With Pembrolizumab\, Followed 
 by Maintenance Pembrolizumab With or Without Nesuparib\, in Patients With 
 Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Ca
 ncer\nEstimated primary completion: 27 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06502743
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438420-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438420)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Cervical Cancer.\nStudy: Oral Axl/M
 er/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pemb
 rolizumab in Patients With Selected Advanced Solid Tumors\nEstimated prima
 ry completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05438420
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180733-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06180733)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Neo-adjuv
 ant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer\nEst
 imated primary completion: 30 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06180733
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06736379-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06736379)
DESCRIPTION:Pembrolizumab\, phase 1\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Intratumoral Delivery of Viral Replicon (saRNA) Particles Expres
 sing IL-12 in Head and Neck Cancer\nEstimated primary completion: 30 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6736379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02717156-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02717156)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: Multicohort Pha
 se II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02717156
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03225664-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03225664)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-smal
 l Cell Lung Cancer That Is Metastatic\, Unresectable\, or Locally Advanced
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03225664
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03295227-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03295227)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Pembrolizumab in Treating Part
 icipants With Unresectable Thymoma or Thymic Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03295227
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319940-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03319940)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Study Evaluating Safety\, Tole
 rability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell
  Lung Cancer (SCLC)\nEstimated primary completion: 31 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03319940
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04729322-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04729322)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Fecal Micr
 obiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab 
 or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD
 -1 Non-responders\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04729322
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04930783-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04930783)
DESCRIPTION:Pembrolizumab\, phase 1\, Melanoma.\nStudy: NeoVax + CDX-301 an
 d Nivolumab or Pembrolizumab in Melanoma\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04930783
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05726370-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05726370)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Preoperative Pembrolizumab and Chemotherapy in Resectable\, Recu
 rrent HNSCC\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05726370
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06049212-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06049212)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: S
 acituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pe
 mbrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06049212
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636734-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06636734)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Lovastatin and Pembrolizumab for the Treatment of Patients With 
 Recurrent or Metastatic Head and Neck Cancer\, LAPP Trial\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06636734
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Study of Precision Treatment f
 or Rare Tumours in China Guided by PDO and NGS\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06692491
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846268-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06846268)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvan
 t ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06846268
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06920810-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT06920810)
DESCRIPTION:Pembrolizumab\, phase 4\, Breast Cancer.\nStudy: Viscum Album f
 or TNBC on Adjuvant Pembrolizumab\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 920810
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT07010393)
DESCRIPTION:Pembrolizumab\, phase 4.\nStudy: Genotype-Driven Neoadjuvant Th
 erapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129772-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07129772)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Perioperative Chemotherapy and
  Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma\nEstimated p
 rimary completion: 31 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07129772
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469774-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07469774)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: BC3195 in Com
 bination With Pembrolizumab in Participants With Locally Advanced or Metas
 tatic Solid Tumors\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07469774
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817901-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07817901)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Melanoma.\nStudy: Phase 1b/2 Clinic
 al Trial to Evaluate the Safety and Efficacy of Combination Therapy With P
 embrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malig
 nant Melanoma\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07817901
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862751-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07862751)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: US/PA/E Imagin
 g for Early Identification of Tumor Response in Patients With Stage II-III
  Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Che
 motherapy\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07862751
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05961761-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05961761)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Propranolol and Pembrolizumab 
 in Advanced Soft Tissue Sarcoma Patients\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05961761
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06160843-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06160843)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Olaparib Tre
 atment for Relapsed or Refractory Peripheral T-Cell Lymphoma\nEstimated pr
 imary completion: January 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06160843
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699836-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06699836)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: CLOVER - C
 CR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriche
 d Regimen\nEstimated primary completion: January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06699836
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725368-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06725368)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pemb
 rolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cel
 l Carcinoma of the Head and Neck\nEstimated primary completion: January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0672536
 8
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217496-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07217496)
DESCRIPTION:Pembrolizumab\, phase 1\, Urothelial Carcinoma.\nStudy: N-803 i
 n Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of U
 rothelial Cancer\nEstimated primary completion: January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07217496
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283822-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07283822)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Amping up With PemJAK\nEstimat
 ed primary completion: January 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07283822
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Safety and Ef
 ficacy of HCB101 in Combination With Multiple Agents in Patients With Adva
 nced Solid Tumors\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388550-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07388550)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Phase I Open-Label Safety Tria
 l of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD
 1-PASC I)\nEstimated primary completion: 1 January 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07388550
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208762-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280105
DTEND;VALUE=DATE:20280106
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05208762)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors\nEstimated primar
 y completion: 5 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05208762
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311721-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06311721)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants W
 ith Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 10 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06311721
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466927-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07466927)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Multi-mode Thermal Therapy Combined With Immunotherapy In 
 Patients With HER2-negative Breast Cancer With Liver Metastases\nEstimated
  primary completion: 15 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07466927
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06831136-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280120
DTEND;VALUE=DATE:20280121
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06831136)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Endoscopic Ultrasound Radiofre
 quency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unres
 ectable and Metastatic Pancreatic Duct Adenocarcinoma\nEstimated primary c
 ompletion: 20 January 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06831136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 acituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus 
 Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With 
 Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50
 % (MK-2870-007)\nEstimated primary completion: 25 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06170788
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03311308-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT03311308)
DESCRIPTION:Pembrolizumab\, phase 1\, Melanoma.\nStudy: A Trial of Pembroli
 zumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma\nEstim
 ated primary completion: 31 January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03311308
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04752826-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04752826)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: BI-1808 as 
 a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanc
 ed Malignancies(Keynote-D20)\nEstimated primary completion: 31 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04752826
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05746208-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05746208)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Lenvatinib Plus Pembrolizumab 
 in Well Differentiated G3 Neuroendocrine Tumors\nEstimated primary complet
 ion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05746208
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470282-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06470282)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Enfortumab Vedotin and Pembr
 olizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer\nEst
 imated primary completion: 31 January 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06470282
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868433-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06868433)
DESCRIPTION:Pembrolizumab\, phase 1\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatme
 nt of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer\nEsti
 mated primary completion: 31 January 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06868433
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719362-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06719362)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Clinical Tria
 l to Evaluate the Safety\, Tolerability and Clinical Efficacy of M3T01 Mon
 otherapy and in Combination With Pembrolizumab and Other Systemic Therapie
 s\nEstimated primary completion: February 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06719362
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652242-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07652242)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Phase 1 Study 
 of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative B
 reast Cancer\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07652242
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807345-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07807345)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are R
 ecurrent or Metastatic\nEstimated primary completion: February 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07807345
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02332668-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02332668)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of Pe
 mbrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tum
 or or Lymphoma (MK-3475-051/KEYNOTE-051)\nEstimated primary completion: 2 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02332668
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07914309-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07914309)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Dexamethasone 
 De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast
  Cancer\nEstimated primary completion: 8 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07914309
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pe
 mbrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated
  primary completion: 15 February 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415031-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07415031)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: A Solid Tumor S
 tudy for Long Term Treatment of Cancer Patients Who Participated in Adagra
 sib Studies\nEstimated primary completion: 16 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07415031
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05064280-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05064280)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase II Study of Pembrolizumab in Combination With Lenvatinib in Patients 
 With TNBC\, NSCLC\, and Other Tumor Types and Brain Metastases\nEstimated 
 primary completion: 28 February 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05064280
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462794-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06462794)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: First In Human 
 Study of CX-801 in Advanced Solid Tumors\nEstimated primary completion: 28
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06462794
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06472583-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06472583)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Preoperative Immunotherapy Combined With Stereotactic Radiation The
 rapy Boost in the Treatment of HER2-negative Breast Cancer\nEstimated prim
 ary completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06472583
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Study of AMXT 1501 and DFMO in Combination With Standard Therapie
 s in Advanced Solid Tumors\nEstimated primary completion: 28 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07287917
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404332-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07404332)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: 5-Azacitidine P
 lus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors\nEstimated prim
 ary completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07404332
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824792-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT06824792)
DESCRIPTION:Pembrolizumab\, phase 4\, Solid Tumors.\nStudy: Optimal Standar
 d Treatment Selection for Solid Tumor Patients by Biologically-informed Mu
 lti-agent System\nEstimated primary completion: 29 February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06824792
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04901741-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04901741)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Olaptesed With Pembrolizumab a
 nd Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreati
 c Cancer\nEstimated primary completion: March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04901741
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05232409-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05232409)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Determine Safet
 y & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pem
 brolizumab in Patients With Metastatic Cancer\nEstimated primary completio
 n: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05232409
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549297-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05549297)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Tebentafusp Regimen
  Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEB
 E-AM)\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05549297
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578664-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05578664)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Efficac
 y of PErioperative PEmbrolizumab Treatment in Patients With Resectable Met
 astases From Kidney Cancer\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05578664
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109467-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06109467)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Neratinib In 
 Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesop
 hageal Cancer\nEstimated primary completion: March 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06109467
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225596-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06225596)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study B
 T8009-230 in Participants With Locally Advanced or Metastatic Urothelial C
 ancer (Duravelo-2)\nEstimated primary completion: March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06225596
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356155-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06356155)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study o
 f Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urotheli
 al Cancer\nEstimated primary completion: March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06356155
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384560-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06384560)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Neoadjuvant Triple Therapy f
 or (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)\nEstimated prima
 ry completion: March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06384560
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06579196-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06579196)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCL
 C and Positive PD-L1\nEstimated primary completion: March 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06579196
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183319-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07183319)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Circula
 ting Tumor DNA Response In Urothelial Cancer\nEstimated primary completion
 : March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07183319
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807163-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07807163)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination Wi
 th Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07807163
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727904-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05727904)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Study to Investigat
 e Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone 
 in Participants With Untreated Advanced Melanoma.\nEstimated primary compl
 etion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05727904
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409844-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07409844)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvan
 t Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III d
 MMR Colon Cancer\nEstimated primary completion: 1 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07409844
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05782361-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280308
DTEND;VALUE=DATE:20280309
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05782361)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: P
 OTENT - Tepotinib in Combination With Pembrolizumab in NSCLC\nEstimated pr
 imary completion: 8 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05782361
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03412877-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280323
DTEND;VALUE=DATE:20280324
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03412877)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 dministration of Autologous T-Cells Genetically Engineered to Express T-Ce
 ll Receptors Reactive Against Neoantigens in People With Metastatic Cancer
 \nEstimated primary completion: 23 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03412877
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05027633-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05027633)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Immunotherapy With Chemotherap
 y and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Parana
 sal Sinuses (I-NAPA)\nEstimated primary completion: 30 March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05027633
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06877650-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06877650)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: First-in-Human Investigation
  of JMT108 Injection in Participants With Advanced Malignant Tumors\nEstim
 ated primary completion: 30 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06877650
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06381154-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06381154)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Photoradiation With Verteporfi
 n to Facilitate Immunologic Activity of Pembrolizumab in Unresectable\, Lo
 cally Advanced or Metastatic Pancreatic Cancer\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06381154
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483334-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06483334)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Stu
 dy of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfort
 umab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Ca
 rcinoma (MK-3475-04C/KEYMAKER-U04)\nEstimated primary completion: 31 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0648
 3334
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341867-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07341867)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Systemic Anti-
 Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotyp
 e\nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07341867
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05356741-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05356741)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: To Access the Safety and Eff
 ects of Intravenous Administration of VIR-5818 Alone and in Combination Wi
 th Pembrolizumab in Adult Participants With Locally Advanced or Metastatic
  HER2-Expressing Cancers\nEstimated primary completion: April 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05356741
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733715-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05733715)
DESCRIPTION:Pembrolizumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Neoadju
 vant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma\nEstimated prim
 ary completion: April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05733715
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06276504-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06276504)
DESCRIPTION:Pembrolizumab\, phase 2/3.\nStudy: Pembrolizumab in Progressive
  Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Withou
 t HIV Infection\nEstimated primary completion: April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06276504
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06340711-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06340711)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Study of Suratadenoturev (OBP-
 301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma\n
 Estimated primary completion: April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06340711
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458347-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07458347)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participa
 nts With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Hom
 olog (KRAS) Mutation\nEstimated primary completion: April 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07458347
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634380-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07634380)
DESCRIPTION:Pembrolizumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Sitagli
 ptin With Pembro in RCC and Melanoma\nEstimated primary completion: 10 Apr
 il 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 634380
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07094113-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280418
DTEND;VALUE=DATE:20280419
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07094113)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: AMG 410 Alone a
 nd in Combination With Other Agents in Participants With KRAS Altered Adva
 nced or Metastatic Solid Tumors\nEstimated primary completion: 18 April 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0709411
 3
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04919629-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04919629)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: APL-2 and Pembrolizumab Versus
  APL-2\, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Tr
 eatment of Recurrent Ovarian\, Fallopian Tube\, or Primary Peritoneal Canc
 er and Malignant Effusion\nEstimated primary completion: 30 April 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04919629
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05313243-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05313243)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Brentuximab 
 Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma\nEstimated pr
 imary completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05313243
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455019-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07455019)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of Bemosubaiabimab Com
 bined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment o
 f Oligometastatic Esophageal Cancer\nEstimated primary completion: 30 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 55019
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465276-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07465276)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
 \nEstimated primary completion: 30 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07465276
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03526835-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03526835)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid T
 umors\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03526835
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128303-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07128303)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Study of GS-531
 9 Given Alone or in Combination in Adults With Solid Tumors\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07128303
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484139-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07484139)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembro
 lizumab (Keytruda) in Surgically Resectable\, HPV Negative Oral Cavity Squ
 amous Cell Carcinoma (OCSCC)\nEstimated primary completion: May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07484139
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05859074-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280504
DTEND;VALUE=DATE:20280505
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05859074)
DESCRIPTION:Pembrolizumab\, phase 1\, Merkel Cell Carcinoma.\nStudy: A Stud
 y of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cance
 r\nEstimated primary completion: 4 May 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05859074
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04348747-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04348747)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Dendritic Cell
  Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain M
 etastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer\nEstim
 ated primary completion: 15 May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04348747
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471974-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04471974)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: ZEN-3694\, Enzalutamide\, and 
 Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostat
 e Cancer\nEstimated primary completion: 31 May 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04471974
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101070-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05101070)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: S-531011 as M
 onotherapy and in Combination With an Immune Checkpoint Inhibitor in Advan
 ced or Metastatic Solid Tumors\nEstimated primary completion: 31 May 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05101070
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05365581-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05365581)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: A Study of ASP2138 Given by It
 self or Given With Other Cancer Treatments in Adults With Stomach Cancer\,
  Gastroesophageal Junction Cancer\, or Pancreatic Cancer\nEstimated primar
 y completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05365581
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05737199-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05737199)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Assessment of the Efficacy and
  Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma\nEstimated pr
 imary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05737199
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05656235-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05656235)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Renal R
 etention in High Grade Upper Tract Urothelial Cancer\nEstimated primary co
 mpletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05656235
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malign
 ancies\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06001658-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06001658)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: Periope
 rative Gemcitabine\, Cisplatin\, and Pembrolizumab in Potentially Resectab
 le Biliary Tract Cancers\nEstimated primary completion: June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06001658
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731478-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06731478)
DESCRIPTION:Pembrolizumab\, phase 3\, Gastric Cancer.\nStudy: Study of TDXd
 \, Chemotherapy\, Pembrolizumab\, and Trastuzumab in First-Line Metastatic
  HER2-Positive Gastric or Gastroesophageal Junction Cancer\nEstimated prim
 ary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06731478
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07385846-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07385846)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Pilot Study of Navigated Focus
 ed Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 
 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency\nEstimated prima
 ry completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07385846
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06902272-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280611
DTEND;VALUE=DATE:20280612
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06902272)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: c
 tDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residua
 l Disease in Non-Small Cell Lung Cancer\nEstimated primary completion: 11 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06902272
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845786-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07845786)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Z
 anzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Sq
 uamous Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1
 5 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07845786
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02621021-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02621021)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: A Phase 2 Trial for
  Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating L
 ymphocytes Plus IL-2 Either Alone or Following the Administration of Pembr
 olizumab\nEstimated primary completion: 16 June 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02621021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05853367-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280624
DTEND;VALUE=DATE:20280625
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05853367)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Study of MK-047
 2 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)\nEst
 imated primary completion: 24 June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05853367
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282509-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07282509)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: S
 afety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With 
 Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer\nEstim
 ated primary completion: 26 June 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07282509
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or 
 Lenvatinib in Advanced Solid Tumors\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0497
 7453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04995003-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04995003)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: HER2 Chimeric Antigen Receptor
  (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Ad
 vanced Sarcoma\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04995003
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05485766-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05485766)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Novel Neoadjuv
 ant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Br
 east Cancer\nEstimated primary completion: 30 June 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05485766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05741164-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05741164)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Propranolol an
 d Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With 
 Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative
  Breast Cancer\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05741164
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545955-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06545955)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Muscle Invasive Bladder Cancer.\n
 Study: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or 
 in Combination With Chemotherapy or Immunotherapy in Participants With Hig
 h-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer\nEstimated pri
 mary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06545955
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822543-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06822543)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Single Arm\, Phase 2 Study of Datopotamab Deruxtecan\, Carboplatin\, and 
 Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small C
 ell Lung Cancer)\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06822543
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868732-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06868732)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: E
 valuation of JSKN016 Combination Therapy in Subjects With NSCLC\nEstimated
  primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06868732
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254585-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07254585)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic He
 ad And Neck Squamous Cell Carcinoma\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0725
 4585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT06031233)
DESCRIPTION:Pembrolizumab\, phase 4.\nStudy: Evaluating the Safety of Short
 ened Infusion Times for dIfferent Oncological Immunotherapie\nEstimated pr
 imary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06031233
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06113809-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06113809)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Palbociclib and Pembrolizumab 
 in Sarcoma\nEstimated primary completion: July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06113809
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284590-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06284590)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Study of the Effica
 cy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF\, in Combination With
  Pembrolizumab\, in Unresectable Melanoma Patients\nEstimated primary comp
 letion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06284590
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789172-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06789172)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1\, First-in-human Study of OKN4395 and Pembrolizumab in Patients W
 ith Solid Tumors\nEstimated primary completion: July 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06789172
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882174-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06882174)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 his Study is Comparing Morning vs Random Scheduling of Standard of Care Pe
 mbrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With 
 Metastatic Non-small Cell Lung Cancer\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06882
 174
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915037-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07915037)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: E
 valuation of the Effect of Time of Administration on the Activity on First
  Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metas
 tatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial\n
 Estimated primary completion: July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07915037
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923190-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05923190)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma\nEst
 imated primary completion: 1 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05923190
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204614-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06204614)
DESCRIPTION:Pembrolizumab\, phase 1\, Urothelial Carcinoma.\nStudy: Drug Sc
 reening Using IMD in Bladder Cancer\nEstimated primary completion: 1 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06204
 614
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764095-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT06764095)
DESCRIPTION:Pembrolizumab\, phase 4\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Loca
 lly Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer\, CAS
 T-AI Trial\nEstimated primary completion: 1 July 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06764095
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198074-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07198074)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: Testing t
 he Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carbo
 platin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMM
 R\, TP53 Mutated Endometrial Cancer\nEstimated primary completion: 1 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07198
 074
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07090499-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280708
DTEND;VALUE=DATE:20280709
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07090499)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Learn About the Study Medicine Called PF-08046876 in People With
  Advanced Solid Tumors\nEstimated primary completion: 8 July 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07090499
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03711032-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03711032)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Muscle Invasive Bladder Cancer.\n
 Study: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With 
 Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Ca
 ncer (HR NMIBC) (MK-3475-676/KEYNOTE-676)\nEstimated primary completion: 3
 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03711032
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187182-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05187182)
DESCRIPTION:Pembrolizumab\, phase 1\, Gastric Cancer.\nStudy: CA-4948 in Co
 mbination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresec
 table Gastric and Esophageal Cancer\nEstimated primary completion: 31 July
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0518
 7182
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05581004-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05581004)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate the Safety\, Pharmacokinetics\, and Activity of Enzelki
 tug as a Single Agent and in Combination With Checkpoint Inhibitor in Part
 icipants With Locally Advanced or Metastatic Solid Tumors\nEstimated prima
 ry completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05581004
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05973864-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05973864)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Capecitabine P
 lus Pembrolizumab in Patients With Triple Negative Breast Cancer After Che
 mo-immunotherapy and Surgery\nEstimated primary completion: August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05973864
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548476-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase na readout est. (NCT07548476)
DESCRIPTION:Pembrolizumab\, phase na\, Urothelial Carcinoma.\nStudy: Acupun
 cture and Exercise for EV-Pembro-Induced Peripheral Neuropathy\nEstimated 
 primary completion: August 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07548476
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634094-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07634094)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Intensive Loc
 oregional Chemoimmunotherapy\, Intradermal Autologous Alpha-DC1 Vaccines\,
  and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer\nEstimated p
 rimary completion: August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07634094
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07809256-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07809256)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Prospective\, Single-center\, Non-randomized\, Interventional Study on th
 e Effectiveness and Safety of Combined Immunotargeted Therapy in Patients 
 With Metastatic Non-small Cell Cancer With a RET Gene Translocation\nEstim
 ated primary completion: August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07809256
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Pa
 rticipants With Solid Tumors\nEstimated primary completion: 4 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087860-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07087860)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Therape
 utic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatme
 nt of Bladder Cancers\nEstimated primary completion: 7 August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07087860
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420439-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07420439)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 reatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Inter
 stitial Lung Disease\nEstimated primary completion: 15 August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07420439
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03516279-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03516279)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab and Dasatinib\, 
 Imatinib Mesylate\, or Nilotinib in Treating Patients With Chronic Myeloid
  Leukemia and Persistently Detectable Minimal Residual Disease\nEstimated 
 primary completion: 31 August 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03516279
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639450-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07639450)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: N-3C01 Monoth
 erapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors\nEs
 timated primary completion: 31 August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07639450
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05613413-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05613413)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for P
 atients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEst
 imated primary completion: September 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05613413
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699212-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06699212)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembr
 olizumab in First-line Treatment of Locoregional Recurrent Squamous Cell C
 arcinoma of the Head and Neck With No Distant Metastases\nEstimated primar
 y completion: September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06699212
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197827-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07197827)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of YL
 242 in Subjects With Advanced Solid Tumors\nEstimated primary completion: 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07197827
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02896335-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02896335)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Palbociclib and Pembrolizumab 
 In Central Nervous System Metastases\nEstimated primary completion: 1 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T02896335
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016399-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07016399)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Da
 rolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA
 \, AR+\, TNBC\nEstimated primary completion: 1 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07016399
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221942-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07221942)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Pembrol
 izumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front
 -Line Metastatic Urothelial Carcinoma\nEstimated primary completion: 1 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07221942
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239741-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05239741)
DESCRIPTION:Pembrolizumab\, phase 3\, Colorectal Cancer.\nStudy: Study of P
 embrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With St
 age IV Colorectal Cancer (MK-3475-C66)\nEstimated primary completion: 19 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05239741
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407920-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07407920)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Ph2 Study for 
 Optimization of Adjunct Systemic Therapy in HER2+ Patients\, MolecularPCR 
 Trial\nEstimated primary completion: 30 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07407920
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668154-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07668154)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Phase II Study to Evaluate t
 he Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Particip
 ants\nEstimated primary completion: 30 September 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07668154
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680088-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07680088)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Phase 2 Study of Pembrolizumab
  and Lenvatinib in Anal Squamous Cell Cancer\nEstimated primary completion
 : 30 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07680088
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04230109-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04230109)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Sacituzumab Go
 vitecan In TNBC\nEstimated primary completion: October 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04230109
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123415-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07123415)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Phase 1 Study
  of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjec
 ts With Advanced Solid Tumors\nEstimated primary completion: October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07123415
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772882-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07772882)
DESCRIPTION:Pembrolizumab\, phase 1\, Ovarian Cancer.\nStudy: Study of Supp
 lemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistan
 t Ovarian\, Fallopian Tube\, and Peritoneal Cancer\nEstimated primary comp
 letion: October 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07772882
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850791-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07850791)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: A Prosp
 ective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Bi
 liary Tract Cancer\nEstimated primary completion: October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07850791
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223047-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-98652
 3 Alone and in Combination With Anti-Cancer Agents in Participants With Ad
 vanced Solid Malignancies\nEstimated primary completion: 13 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551142-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06551142)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of GSK5
 764227 in Participants With Advanced Solid Tumors (EMBOLD)\nEstimated prim
 ary completion: 16 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06551142
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037004-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281024
DTEND;VALUE=DATE:20281025
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07037004)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Adding 
 a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment 
 of Renal Cell Cancer After Surgery\nEstimated primary completion: 24 Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 037004
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04675710-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04675710)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab\, Dabrafenib\, a
 nd Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic 
 Thyroid Cancer\nEstimated primary completion: 30 October 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04675710
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952453-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05952453)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Newly Diagnos
 ed Stage III/IV Ovarian Cancer\, Neoadjuvant Carbo/Taxol/Pembro\, Maintena
 nce Olaparib/Pembro\nEstimated primary completion: 30 October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05952453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04613596-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT04613596)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizu
 mab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRA
 S G12C Mutation KRYSTAL-7\nEstimated primary completion: 31 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04613596
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691476-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07691476)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase
  2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizuma
 b in Subjects With Resectable Clear Cell Renal Cell Carcinoma\nEstimated p
 rimary completion: 31 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07691476
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283731-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07283731)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Phase 2 Trial of Zanzalintinib
  and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue S
 arcoma\nEstimated primary completion: 1 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07283731
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06923475-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281106
DTEND;VALUE=DATE:20281107
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06923475)
DESCRIPTION:Pembrolizumab\, phase 2/3.\nStudy: Neoadjuvant Gemcitabine and 
 Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront S
 urgery for Patients With Primary Resectable and Borderline Resectable Peri
 hilar and Distal Cholangiocarcinoma\nEstimated primary completion: 6 Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6923475
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932067-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07932067)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate
 -Risk Head and Neck Cancer\nEstimated primary completion: 15 November 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07932067
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06673628-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06673628)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab Plus Lenvatinib 
 in Unresectable Cutaneous Angiosarcoma Patients\nEstimated primary complet
 ion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06673628
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793215-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06793215)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab V
 ersus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Partici
 pants With Previously Untreated\, KRAS G12C-Mutated\, Advanced or Metastat
 ic Non-Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 
 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06793215
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04121455-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04121455)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Glioblastoma Treatment With 
 Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients\nE
 stimated primary completion: December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04121455
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05425576-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05425576)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: OT-101 in Combination With Pem
 brolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Resp
 ond to Checkpoint Inhibition\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05425576
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumo
 rs (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583708-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05583708)
DESCRIPTION:Pembrolizumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Phase 
 II Study of Peptide Receptor Radionuclide Therapy in Combination With Immu
 notherapy for Patients With Merkel Cell Cancer\nEstimated primary completi
 on: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05583708
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06137378-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06137378)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]\nE
 stimated primary completion: December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06137378
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tum
 ors\nEstimated primary completion: December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07089992-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07089992)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Study of Pembrolizumab in Pe
 ople With Ultra-Rare Sarcomas\nEstimated primary completion: December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07089992
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360743-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07360743)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: I
 mmunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With H
 igh PD-L1 Levels\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07360743
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Pembrolizumab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficac
 y and Safety of Zanidatamab With Standard-of-care Therapy Against Standard
 -of-care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimate
 d primary completion: 1 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894459-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06894459)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Prospective\, Multicenter\, Multicohort Phase II Study: Evalua
 ting the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a 
 PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryng
 eal and Hypopharyngeal Squamous Cell Carcinoma\nEstimated primary completi
 on: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06894459
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07017829-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07017829)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: G
 T103 in Combination With Pembrolizumab for the Treatment of Advanced or Me
 tastatic STK11 Mutant Non-Small Cell Lung Cancer\nEstimated primary comple
 tion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07017829
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410676-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07410676)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab
  in Advanced Solid Tumors\nEstimated primary completion: 21 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07410676
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01174121-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT01174121)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients Wit
 h Metastatic Cancer\nEstimated primary completion: 27 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT01174121
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06055465-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06055465)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Smal
 l Cell Lung Cancer\nEstimated primary completion: 30 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06055465
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Pembrolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neo
 adjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nE
 stimated primary completion: 30 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated pr
 imary completion: 30 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02721732-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02721732)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in Treating Pati
 ents With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic\
 nEstimated primary completion: 31 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02721732
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03449238-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03449238)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Bra
 in Metastases In Breast Cancer Patients\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03449238
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382559-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05382559)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of ASP3
 082 in Adults With Advanced Solid Tumors\nEstimated primary completion: 31
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05382559
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07622186)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SKB571 Combination Therapy in Participants With Non-Small Cell L
 ung Cancer (NSCLC)\nEstimated primary completion: 31 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687875-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07687875)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Oncolytic Virotherapy to Enhan
 ce PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatc
 h Repair (pMMR) Rectal Cancer\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076878
 75
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823491-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07823491)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Pembrolizumab and Radiation Th
 erapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treat
 ment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Lipos
 arcoma of the Extremity or Trunk Wall\nEstimated primary completion: 31 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07823491
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098132-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05098132)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of STK-012 Alone and With Other Treatments in Patients With Advance
 d Lung Cancer and Other Cancers\nEstimated primary completion: January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05098132
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05692999-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05692999)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Maintenance Pembrolizumab at U
 sual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study\nEst
 imated primary completion: January 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05692999
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06016920-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06016920)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Safety and Efficacy of VB10.
 16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma\nE
 stimated primary completion: January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06016920
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045767-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06045767)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 -Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced 
 Non-small Lung Cancer\nEstimated primary completion: January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06045767
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347210-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07347210)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Evaluation of UCPVax Vaccine +
 /- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in P
 atients With Unmethylated MGMT Glioblastoma\nEstimated primary completion:
  January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07347210
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883759-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07883759)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant Pembrol
 izumab in Patients With High Risk\, Stage IIB/IIC Cutaneous Melanoma: a Si
 ngle Arm Proof of Concept Phase IIA Study.\nEstimated primary completion: 
 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07883759
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06004336-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06004336)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Rando
 mized Trial of Maintenance Systemic Therapy After Radiation for Oligometas
 tatic Renal Cell Carcinoma (ASTROs)\nEstimated primary completion: 1 Janua
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 004336
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686744-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07686744)
DESCRIPTION:Pembrolizumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Neoanti
 gen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma\nEstimated 
 primary completion: 1 January 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07686744
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT\
 ; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2
 870-023]\nEstimated primary completion: 12 January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610525-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07610525)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Blood and imag
 E-guided Optimization of Neoadjuvant Therapy in People With Early Stage Tr
 iple-negative Breast cancER - the BETTER Trial\nEstimated primary completi
 on: 15 January 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07610525
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989112-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06989112)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: DESTINY-E
 ndometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostom
 ig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+)
 \, Mismatch Repair Proficient (pMMR) Endometrial Cancer\nEstimated primary
  completion: 19 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06989112
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552558-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07552558)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: Ficerafusp Alfa\, Pembrolizumab\, and Stereotactic Body Radiot
 herapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)\nEstimated
  primary completion: 31 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07552558
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624644-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06624644)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Melanoma.\nStudy: A Trial of LNS880
 1 With or Without Pembrolizumab in Patients With Refractory Melanoma\nEsti
 mated primary completion: February 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06624644
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643519-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07643519)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Neoadju
 vant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Canc
 er and Upper Tract Urothelial Carcinoma\nEstimated primary completion: Feb
 ruary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07643519
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840456-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07840456)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Safety and Efficacy of Ruxolit
 inib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The 
 Phase 2 InflammaSTOP Trial\nEstimated primary completion: February 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07840456
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857486-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07857486)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Reduction of N
 eoadjuvant Treatment in Early Triple-Negative Breast Cancer\nEstimated pri
 mary completion: February 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07857486
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07166601-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07166601)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: M0324 as Monoth
 erapy and in Combination With Pembrolizumab or Chemotherapy in Participant
 s With Selected Advanced Solid Tumors\nEstimated primary completion: 23 Fe
 bruary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07166601
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562830-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290226
DTEND;VALUE=DATE:20290227
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05562830)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: A Sub
 study of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/
 L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (
 MK-3475-04A)\nEstimated primary completion: 26 February 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05562830
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218003-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07218003)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab 
 in Bladder Cancer and Other Solid Tumors Associated With Nectin-4\nEstimat
 ed primary completion: 28 February 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07218003
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176312-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07176312)
DESCRIPTION:Pembrolizumab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab i
 n Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positi
 ve Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients\nEstimated pr
 imary completion: March 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07176312
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262619-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07262619)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: EIK1005-
 002: A Clinical Research Study Evaluating EIK1005\, a Werner Helicase Inhi
 bitor\, as Monotherapy and in Combination With Pembrolizumab in Participan
 ts With Advanced Solid Tumors Including Microsatellite Instability High (M
 SI-H) Tumors\nEstimated primary completion: March 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07262619
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740941-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07740941)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: NeoAdjuvant\, Spare
 -Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma\nEstimated primary comple
 tion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07740941
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669572-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290326
DTEND;VALUE=DATE:20290327
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06669572)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Lenvatinib and Pembrolizumab t
 o Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After In
 itial Treatment\nEstimated primary completion: 26 March 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06669572
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical 
 Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003
 ).\nEstimated primary completion: 27 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05651594-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05651594)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Propranolol in Combination Wit
 h Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectabl
 e Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction A
 denocarcinoma\nEstimated primary completion: 30 March 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05651594
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07302347-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07302347)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: A St
 udy of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors 
 or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (M
 K-3475-G21/KEYNOTE-G21)\nEstimated primary completion: 30 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07302347
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05394103-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05394103)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Highly Select
 ive CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors\nEstimated prima
 ry completion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05394103
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05721755-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05721755)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Combining Radiation Therapy With Immunotherapy for the Treatment
  of Metastatic Squamous Cell Carcinoma of the Head and Neck\nEstimated pri
 mary completion: 31 March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05721755
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07572123-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT07572123)
DESCRIPTION:Pembrolizumab\, phase 2/3.\nStudy: Evaluating the Addition of M
 aintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy a
 nd Autologous Stem Cell Transplant Alone for High-risk Patients With Relap
 sed or Refractory Hodgkin Lymphoma\nEstimated primary completion: 31 March
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0757
 2123
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06556563-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06556563)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: EF-41/KEYNOTE D58: Phase 3 Stu
 dy of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Dia
 gnosed Glioblastoma\nEstimated primary completion: April 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06556563
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244393-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07244393)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Lutetium (177Lu) DGUL Combined
  With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer\nEs
 timated primary completion: April 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07244393
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840001-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07840001)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Neoadju
 vant Belzutifan Plus Pembrolizumab in High-Risk\, Locally Advanced Clear C
 ell Renal Cell Carcinoma\nEstimated primary completion: April 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07840001
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644039-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07644039)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Study of PM54 in Combination
  With Immunotherapy in Adult Participants With Advanced Malignancies\nEsti
 mated primary completion: 2 April 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07644039
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07886905-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290408
DTEND;VALUE=DATE:20290409
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07886905)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pulsed Stereotactic Ablative R
 adiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer\nEstimated
  primary completion: 8 April 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07886905
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05603910-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290415
DTEND;VALUE=DATE:20290416
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05603910)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Phase 1 Clinical Trial of Lenv
 atinib\, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for p
 MMR Recurrent/Unresectable Endometrial Carcinoma\nEstimated primary comple
 tion: 15 April 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05603910
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06632327)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: C
 omparing Impact of Treatment Before or After Surgery in Patients With Stag
 e II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary complet
 ion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06632327
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05318573-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05318573)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate Safety\, Efficacy of FF-10832 in Combo With Pembrolizum
 ab in Urothelial & Non-small Cell Lung Cancer\nEstimated primary completio
 n: May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05318573
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812858-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06812858)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: PD-1 Inhibitors Maintenance fo
 r cHL Post-autoHCT\nEstimated primary completion: May 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06812858
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835569-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06835569)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Soli
 d Tumors With KRAS Mutations\nEstimated primary completion: May 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06835569
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633613-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT07633613)
DESCRIPTION:Pembrolizumab\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: P
 harmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the T
 umor Microenvironment\, Which May Explain the Efficacy of Post-immunothera
 py Chemotherapy.\nEstimated primary completion: May 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07633613
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06137144-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06137144)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: AZD3470 as Monotherapy or in
  Combination With Anticancer Agent(s) in Participants With Haematologic Ma
 lignancies.\nEstimated primary completion: 3 May 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06137144
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05555732-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290511
DTEND;VALUE=DATE:20290512
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05555732)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: D
 atopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinu
 m Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)\nEstimate
 d primary completion: 11 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05555732
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349303-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07349303)
DESCRIPTION:Pembrolizumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant Pembrol
 izumab in Patients With Stage IIb/c Melanoma\nEstimated primary completion
 : 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07349303
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480552-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290526
DTEND;VALUE=DATE:20290527
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06480552)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: An Open-label D
 ose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activ
 ity of TEV-56278 Alone or in Combination With Pembrolizumab in Participant
 s With Advanced or Metastatic Solid Tumors\nEstimated primary completion: 
 26 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06480552
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889232-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07889232)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic No
 n-Small Cell Lung Cancer\nEstimated primary completion: 31 May 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07889232
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06245889-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06245889)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: PET Dynamics t
 o Response-Adapted Neoadjuvant Therapy in TNBC\nEstimated primary completi
 on: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06245889
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400472-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06400472)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Sofe-M in Participants With Selected Advanced Solid Tumors\nEsti
 mated primary completion: June 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06400472
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452224-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07452224)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: I
 LKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer\nEstimat
 ed primary completion: June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07452224
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863402-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06863402)
DESCRIPTION:Pembrolizumab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Nemtab
 rutinib and Pembrolizumab for the Treatment of Richter Transformation\, Di
 ffuse Large B-cell Lymphoma Subtype\nEstimated primary completion: 1 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06863
 402
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276399-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07276399)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Amivantamab in Addition to Standard of Care Agents (S
 OC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head
  and Neck Cancer\nEstimated primary completion: 18 June 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07276399
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04671667-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04671667)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Testing What Happens When an Immunotherapy Drug (Pembrolizumab) 
 is Given by Itself Compared to the Usual Treatment of Chemotherapy With Ra
 diation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma\
 nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04671667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287995-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07287995)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of AS
 P2998 Given by Itself and Given With Standard Therapies in People With Sol
 id Tumors\nEstimated primary completion: 30 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07287995
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221474-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07221474)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemother
 apy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)\nEstimate
 d primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07221474
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667335-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07667335)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: Enfor
 tumab Vedotin\, Pembrolizumab and Quemliclustat for the Treatment of Unres
 ectable Locally Advanced and Metastatic Urothelial Cancer\nEstimated prima
 ry completion: 16 July 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07667335
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684599-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07684599)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: A Study t
 o Investigate Mocertatug Rezetecan as Maintenance Treatment for Participan
 ts With MMRp Endometrial Cancer (BEHOLD-Endometrial02)\nEstimated primary 
 completion: 23 July 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07684599
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Pembrolizumab\, phase 4\, Solid Tumors.\nStudy: The FLOTILLA St
 udy: Providing Continued Access to The Study Medicines Encorafenib and Bin
 imetinib for Participants in Prior Clinical Trials\nEstimated primary comp
 letion: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05203172
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021989-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07021989)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: ctDNA-Guided Therapy for Relap
 sed/Refractory Hodgkin Lymphoma\nEstimated primary completion: 31 July 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07021989
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04555226-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase na readout est. (NCT04555226)
DESCRIPTION:Pembrolizumab\, phase na\, Cervical Cancer.\nStudy: The Efficac
 y of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)\n
 Estimated primary completion: August 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04555226
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06960395-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06960395)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Safety and Prel
 iminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants 
 With Locally Advanced or Metastatic Solid Tumors\nEstimated primary comple
 tion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06960395
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEsti
 mated primary completion: 25 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081244-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06081244)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: NeoAdj. Therap
 y Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk\, 
 Triple-neg. EBC (ADAPT-TN-III)\nEstimated primary completion: September 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0608124
 4
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06493552-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06493552)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Solid Tumors.\nStudy: Modular Trial
  of sEphB4-HSA in EphrinB2-High Solid Tumors\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06493552
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976944-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06976944)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Pembrolizumab 
 + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer\nEstimated 
 primary completion: September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06976944
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269158-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07269158)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Pha
 se IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Main
 tenance Therapy in Patients With Advanced Biliary Tract Cancer\nEstimated 
 primary completion: September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07269158
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301268-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07301268)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: GI-102 Alone or With Pembroliz
 umab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype
  Glioblastoma and IDH Mutated Grade 4 Astrocytoma\nEstimated primary compl
 etion: 1 September 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07301268
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469944-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06469944)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Substudy 06C: A Study of Inv
 estigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Parti
 cipants With First-Line Locally Advanced Unresectable/Metastatic Gastroeso
 phageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)\nEstimated primary compl
 etion: 12 September 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06469944
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743190-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290922
DTEND;VALUE=DATE:20290923
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07743190)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: A Phase II Stu
 dy of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant 
 Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Pat
 ients With High Tumor-Infiltrating Lymphocytes (TILs)\nEstimated primary c
 ompletion: 22 September 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07743190
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808151-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07808151)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Neoadjuvant Pembrolizumab and 
 Porustobart in Resectable pMMR/MSS Colon Cancer\nEstimated primary complet
 ion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07808151
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888816-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07888816)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Optimizing Response to Immunotherapy With Online Adaptive Pulsed
  Radiotherapy in Incurable Head and Neck Cancers\nEstimated primary comple
 tion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07888816
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04
  (TP04)]\nEstimated primary completion: 30 September 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06558214-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06558214)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: OPTIMUS PRIME: Safety and Feas
 ibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery 
 and Pembrolizumab for Recurrent GlIoblastoMa\, A randomizEd Trial\nEstimat
 ed primary completion: October 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06558214
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368985-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07368985)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Pembrolizuma
 b and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
 \nEstimated primary completion: October 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07368985
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695311-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07695311)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: EWSR1 Immunotherapy in Ewing S
 arcoma and DSRCT\nEstimated primary completion: October 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07695311
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744126-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07744126)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study to Assess Adverse Events\, Change in Disease Activity an
 d Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembro
 lizumab for First-Line Treatment of Adult Participants With Recurrent or M
 etastatic Head and Neck Squamous Cell Carcinoma\nEstimated primary complet
 ion: October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07744126
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773987-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07773987)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction
  and Unmasking of Tumor Antigenicity in the Microenvironment for Head and 
 Neck Cancer\nEstimated primary completion: October 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07773987
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06093425-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06093425)
DESCRIPTION:Pembrolizumab\, phase 3\, Gastric Cancer.\nStudy: Combination o
 f Osemitamab (TST001)\, Pembrolizumab and Chemotherapy as First-line Thera
 py in Advanced or Metastatic GC/GEJ Adenocarcinoma\nEstimated primary comp
 letion: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06093425
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908979-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07908979)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Risk-En
 abled Therapy After Initiating EV/Pembro for Bladder Cancer\nEstimated pri
 mary completion: 1 October 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07908979
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428409-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06428409)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinic
 al Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestin
 al Cancers (MK-9999-02A)\nEstimated primary completion: 16 October 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06428409
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275216-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291020
DTEND;VALUE=DATE:20291021
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07275216)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab in Combination W
 ith Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Inel
 igible for Standard Treatment\nEstimated primary completion: 20 October 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0727521
 6
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors\n
 Estimated primary completion: 30 October 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05187338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05957081-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05957081)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Study to Assess
  the Safety\, Tolerability\, and Blood Concentration of PMC-309\nEstimated
  primary completion: 30 October 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05957081
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06898970-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06898970)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Intratumoral Vusolimogene Oder
 parepvec (VO) in Combination With Pembrolizumab for Angiosarcoma\nEstimate
 d primary completion: 31 October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06898970
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786428-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07786428)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Tailored Neoad
 juvant Chemoimmunotherapy for Stage I TNBC\nEstimated primary completion: 
 31 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07786428
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732634-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07732634)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resec
 table\, Locally Advanced Head-Neck Cancer\nEstimated primary completion: N
 ovember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07732634
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197322-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05197322)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: NEOadjuvan
 t PembRolizumab In Stratified Medicine - ColoRectal Cancer\nEstimated prim
 ary completion: 1 November 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05197322
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: K
 EYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Partici
 pants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Vir
 al Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)\nEst
 imated primary completion: 15 November 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976021-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06976021)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Immune PET a
 nd Proteomics for the Assessment of Response to Spatially Fractionated or 
 Palliative Radiotherapy With or Without Immunotherapy\nEstimated primary c
 ompletion: December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06976021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910942-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07910942)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1 Trial of KAN-001 With Pembrolizumab\, With or Without Chemotherap
 y\, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer\nEstima
 ted primary completion: December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07910942
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04938817-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291210
DTEND;VALUE=DATE:20291211
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04938817)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Safety and Efficacy Study of
  Investigational Agents as Monotherapy or in Combination With Pembrolizuma
 b (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (E
 S-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)\nEstimate
 d primary completion: 10 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04938817
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06724042-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06724042)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Study of ISM593
 9 in Patients With Advanced and/or Metastatic Solid Tumors\nEstimated prim
 ary completion: 30 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06724042
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Study of Patri
 tumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Partic
 ipants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low 
 Positive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\n
 Estimated primary completion: 31 December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805864-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06805864)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab Concurrent With 
 and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenoc
 arcinoma\nEstimated primary completion: 31 December 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06805864
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610941-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07610941)
DESCRIPTION:Pembrolizumab\, phase 1.\nStudy: Phase 1 Open Label Trial of MS
 T-0312 Alone and in Combination in Subjects With Solid Malignancies\nEstim
 ated primary completion: 31 December 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07610941
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07632235-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07632235)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: A Multicenter\, Prospective\
 , Randomized\, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizuma
 b and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin
  in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic I
 ntrahepatic Cholangiocarcinoma\nEstimated primary completion: 31 December 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07632
 235
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607185-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06607185)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutan
 t Solid Tumors\nEstimated primary completion: January 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06607185
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745882-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06745882)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 rospective Trial Assessing Real World Outcomes Response to Pembro in Black
  Patients w/ NSCLC\nEstimated primary completion: January 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06745882
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04267848-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04267848)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 esting the Addition of a Type of Drug Called Immunotherapy to the Usual Ch
 emotherapy Treatment for Non-small Cell Lung Cancer\, an ALCHEMIST Treatme
 nt Trial (Chemo-IO [ACCIO])\nEstimated primary completion: 31 January 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04267848
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801027-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT07801027)
DESCRIPTION:Pembrolizumab\, phase 4.\nStudy: A Trial of Pembrolizumab With 
 Chemotherapy or Chemoradiotherapy in Participants From India With Differen
 t Types of Cancer (MK-3475-G44/KEYNOTE-G44)\nEstimated primary completion:
  31 January 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07801027
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913568-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07913568)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: A Phase II Investigator-initia
 ted Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With R
 ecurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-bas
 ed Chemotherapy（NCCH2407/MK014）\nEstimated primary completion: 31 Janu
 ary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7913568
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579195-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300201
DTEND;VALUE=DATE:20300202
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07579195)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Consolidative Therapy After 
 EV + Pembrolizumab in Muscle Invasive Bladder Cancer\, REINFORCE Trial\nEs
 timated primary completion: 1 February 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07579195
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619599-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300210
DTEND;VALUE=DATE:20300211
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07619599)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Res
 ponse Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pe
 mbrolizumab\nEstimated primary completion: 10 February 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07619599
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067283-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300225
DTEND;VALUE=DATE:20300226
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05067283)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of Cald
 erasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)\nEstim
 ated primary completion: 25 February 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05067283
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730021-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07730021)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of AS
 P388B Given by Itself and With Standard Therapies in Participants With Sol
 id Tumors\nEstimated primary completion: 28 February 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07730021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05215340-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05215340)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-li
 ne Treatment of Subjects With Advanced or Metastatic NSCLC Without Actiona
 ble Genomic Alterations\nEstimated primary completion: 4 March 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05215340
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182591-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300318
DTEND;VALUE=DATE:20300319
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07182591)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of DS53
 61b in Participants With Advanced Solid Tumors\nEstimated primary completi
 on: 18 March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07182591
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566156-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07566156)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: Enfortu
 mab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiothe
 rapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)\nEstima
 ted primary completion: 31 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07566156
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Study o
 f Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot
  Be Removed or Has Spread\nEstimated primary completion: April 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03547973
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750158-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300405
DTEND;VALUE=DATE:20300406
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07750158)
DESCRIPTION:Pembrolizumab\, phase 3\, Colorectal Cancer.\nStudy: Zanzalinti
 nib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa 
 in Participants With Colorectal Cancer With Molecular Residual Disease\nEs
 timated primary completion: 5 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07750158
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06899126-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300424
DTEND;VALUE=DATE:20300425
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06899126)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Trastuzumab Deruxtecan\, Pembrolizumab\, and Platinum-based Chemot
 herapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer\nEstim
 ated primary completion: 24 April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06899126
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05719558-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05719558)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study of ASP1
 002 in Adults for Treatment of Solid Tumors\nEstimated primary completion:
  30 April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05719558
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645625-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT07645625)
DESCRIPTION:Pembrolizumab\, phase 4\, Cervical Cancer.\nStudy: Pembrolizuma
 b Registry for Outcomes and Treatment Evaluation in Cervical Cancer\nEstim
 ated primary completion: May 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07645625
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841354-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06841354)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: A Study of Sac
 ituzumab Tirumotecan (Sac-TMT\, MK-2870) as Monotherapy and in Combination
  With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast 
 Cancer (MK-2870-011/TroFuse-011)\nEstimated primary completion: 18 May 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06841354
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05200559-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05200559)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: T-regulator
 y Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Me
 tastatic Solid Tumors\nEstimated primary completion: 31 May 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05200559
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06270706-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06270706)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Phase 1 Study
  of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: June 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06270706
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018570-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07018570)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: An Open Label Phase 2 Study of
  Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and
  Short Radiation for Patients With Locally Advanced Gastroesophageal Junct
 ion Adenocarcinoma\nEstimated primary completion: June 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07018570
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783581-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07783581)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Proton Spatially Fractionated 
 Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With 
 Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Rad
 iation-Naive Locoregionally Recurrent Oral Cavity Cancer\, OSPRI Trial\nEs
 timated primary completion: 1 June 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07783581
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05131919-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05131919)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Pembrolizu
 mab for Locally Advanced\, Irresectable\, Non-metastatic dMMR Colorectal C
 ancers\nEstimated primary completion: July 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05131919
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007273-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07007273)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab for Advanced Cut
 aneous Sarcomas Not Including Angiosarcoma\nEstimated primary completion: 
 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07007273
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046923-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07046923)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of LY4175408 in Participants With Advanced Cancer\nEstimated primar
 y completion: July 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07046923
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733466-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07733466)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Open-Label Neoadjuvant Pembrol
 izumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity
  Squamous Cell Carcinoma\nEstimated primary completion: July 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07733466
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751042-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300717
DTEND;VALUE=DATE:20300718
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07751042)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Phase 1/2 Stu
 dy of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monothe
 rapy or in Combination With Pembrolizumab\nEstimated primary completion: 1
 7 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07751042
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of DS-3939a in Participants With Solid Tumors\nEstimated primary 
 completion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07739966
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05954312-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT05954312)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A First-in-Huma
 n (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Par
 ticipants With Advanced Solid Tumors\nEstimated primary completion: 31 Aug
 ust 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5954312
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488482-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06488482)
DESCRIPTION:Pembrolizumab\, phase 3\, Melanoma.\nStudy: Assessment of Short
  Immunotherapy After Radical Surgery of High-risk Malignant Melanoma\nEsti
 mated primary completion: September 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06488482
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762703-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07762703)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Breast Cancer.\nStudy: Combination 
 Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic\, 
 PD-L1 Negative (CPS<10)\, gBRCA Negative\, Triple Negative Breast Cancer I
 ncluding BreakVax ImmunoTreatment (Designed and Manufactured Per Patient)\
 , Chemotherapy and Anti PD-1 Therapy\nEstimated primary completion: Septem
 ber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7762703
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762716-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07762716)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Combination Immunotherapy Tr
 eatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and 
 Manufactured Per Patient)\, Chemotherapy and Anti PD-1 Therapy\nEstimated 
 primary completion: September 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07762716
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872553-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300924
DTEND;VALUE=DATE:20300925
SUMMARY:Pembrolizumab: Phase 4 readout est. (NCT07872553)
DESCRIPTION:Pembrolizumab\, phase 4\, Renal Cell Carcinoma.\nStudy: A Study
  of Treatment Delivery Preference In People With Kidney Cancer\nEstimated 
 primary completion: 24 September 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07872553
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07300475-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07300475)
DESCRIPTION:Pembrolizumab\, phase 1\, Breast Cancer.\nStudy: Personalized C
 ancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients\nEs
 timated primary completion: 30 September 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07300475
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05920798-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301028
DTEND;VALUE=DATE:20301029
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05920798)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: Vaccine Therapy Plus Pembrol
 izumab in Treating Advanced Ovarian\, Fallopian Tube\, or Primary Peritone
 al Cavity Cancer\nEstimated primary completion: 28 October 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05920798
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 atient Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859592-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07859592)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: L
 abyrinthin Vaccination in Veterans With Lung Adenocarcinoma\nEstimated pri
 mary completion: 30 November 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07859592
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: I-SPY TRIAL: N
 eoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer\n
 Estimated primary completion: December 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346053-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07346053)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: The Impact of Time-of-day Admi
 nistration of EV/P on Objective Response Rate in Adults With Advanced Blad
 der Cancer\nEstimated primary completion: December 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07346053
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485296-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07485296)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Effect of Postbiotics on Microbiota and Systemic Immunomodulatio
 n of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and 
 Neck Squamous Cell Carcinoma (RM HNSCC)\nEstimated primary completion: Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07485296
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06146777-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06146777)
DESCRIPTION:Pembrolizumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Multi-c
 lassifier System for Stratifying Stage III Papillary Renal Cell Carcinoma 
 of Receiving Adjuvant Therapy\nEstimated primary completion: 1 December 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614677
 7
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247110-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07247110)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Clinical Stud
 y of MK-4716 in People With Certain Solid Tumors (MK-4716-001)\nEstimated 
 primary completion: 1 December 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07247110
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393374-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301216
DTEND;VALUE=DATE:20301217
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06393374)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Sacituzumab Ti
 rumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achi
 eve pCR (MK-2870-012)\nEstimated primary completion: 16 December 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06393374
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524544-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06524544)
DESCRIPTION:Pembrolizumab\, phase 3\, Urothelial Carcinoma.\nStudy: A Study
  Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy
  Versus Standard of Care in the Treatment of Advanced Urothelial Cancer\nE
 stimated primary completion: 31 December 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06524544
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061977-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07061977)
DESCRIPTION:Pembrolizumab\, phase 3\, Cervical Cancer.\nStudy: Induction Pe
 mbrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiati
 on and Pembrolizumab Maintenance Compared to Standard Chemoradiation With 
 Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical 
 Cancer\nEstimated primary completion: 31 December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07061977
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890493-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07890493)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: I
 mmune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiot
 a Transplant in Advanced Non-Small Cell Lung Cancer\nEstimated primary com
 pletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07890493
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03725059-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310124
DTEND;VALUE=DATE:20310125
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03725059)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Study of Pembr
 olizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemothe
 rapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen
  Receptor-Positive\, Human Epidermal Growth Factor Receptor 2-Negative (ER
 +/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)\nEstimated primary comple
 tion: 24 January 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03725059
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06543576-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06543576)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Cervical Cancer.\nStudy: External B
 eam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherap
 y for the Treatment of Stage IVB Cervical Cancer\nEstimated primary comple
 tion: 31 January 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06543576
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172256-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07172256)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs\nEstim
 ated primary completion: February 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07172256
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: A Study to Evaluate the Safety\, Tolerability\, Drug Levels\, and
  Preliminary Efficacy of BMS-986507 Combinations in Adult Participants Wit
 h Advanced Solid Tumors\nEstimated primary completion: 26 February 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673887-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07673887)
DESCRIPTION:Pembrolizumab\, phase 3\, Gastric Cancer.\nStudy: A Study of AS
 P2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric 
 Cancer\nEstimated primary completion: 28 February 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07673887
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923877-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07923877)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Induction Chemoimmunotherapy t
 o Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Can
 cer\nEstimated primary completion: 28 February 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07923877
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749586-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07749586)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study to Ev
 aluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced
  Solid Tumors\nEstimated primary completion: 31 March 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07749586
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06343402-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06343402)
DESCRIPTION:Pembrolizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: O
 pen-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell
  Lung Cancer\nEstimated primary completion: April 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06343402
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663747-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07663747)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Enfortumab Vedotin + Pembroliz
 umab Induction to Spare the Bladder in MIBC\nEstimated primary completion:
  1 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07663747
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06134375-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310626
DTEND;VALUE=DATE:20310627
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06134375)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Breast Cancer.\nStudy: A Study of T
 etrathiomolybdate (TM) Plus Capecitabine\nEstimated primary completion: 26
  June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06134375
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384352-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06384352)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Safety\,Tolerab
 ility\, Pharmacokinetics\, and Efficacy of YL211 in Patients With Advanced
  Solid Tumors\nEstimated primary completion: 30 June 2031. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06384352
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06724016-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT06724016)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Dose Escalation
  and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or
  Metastatic Solid Tumors\nEstimated primary completion: July 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06724016
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04990921-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04990921)
DESCRIPTION:Pembrolizumab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Palliative Radiation Combined with Pembrolizumab in Unrese
 ctable Metastatic Stage IV Breast Cancer\nEstimated primary completion: 1 
 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04990921
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232602-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310708
DTEND;VALUE=DATE:20310709
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07232602)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Urothelial Carcinoma.\nStudy: KEYMA
 KER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfort
 umab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-0
 4D/KEYMAKER-U04)\nEstimated primary completion: 8 July 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07232602
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460206-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07460206)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab Plus Lenvatinib 
 in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment\nEst
 imated primary completion: August 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07460206
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pem
 brolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemothe
 rapy in First-line Metastatic Non-small Cell Lung Cancer Participants With
  Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594015-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07594015)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Pembroliz
 umab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Ca
 ncer After Progression on or Following First-Line Immunotherapy Maintenanc
 e\nEstimated primary completion: 31 August 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07594015
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05155033-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05155033)
DESCRIPTION:Pembrolizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Phase I
 I Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma a
 nd Renal Cell Carcinoma\nEstimated primary completion: 1 September 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05155033
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509099-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07509099)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemot
 herapy in R/M HNSCC\nEstimated primary completion: 30 September 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07509099
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290894-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07290894)
DESCRIPTION:Pembrolizumab\, phase 2.\nStudy: Pembrolizumab Plus Lenvatinib 
 in Vulvar Cancer Patients: MITO VULVA-01\nEstimated primary completion: Oc
 tober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07290894
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660094-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311022
DTEND;VALUE=DATE:20311023
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07660094)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
 glatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage
  IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)\nEstimated pr
 imary completion: 22 October 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07660094
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Pembrolizumab\, phase 3\, Cervical Cancer.\nStudy: A Clinical S
 tudy of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizuma
 b (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-287
 0-036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary completion: 29 O
 ctober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07216703
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07829783)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: A Clinical Trial of Sacituzuma
 b Tirumotecan (Sac-TMT\, MK-2870) and Pembrolizumab (MK-3475A) in Particip
 ants With Bladder Cancer (MK-2870-055)\nEstimated primary completion: 17 N
 ovember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07829783
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04541108-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04541108)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: Phase 0 Master 
 Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies\nEstim
 ated primary completion: December 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04541108
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720180-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311201
DTEND;VALUE=DATE:20311202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07720180)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of Auto
 logous\, Metabolically Optimized\, CD137+ Tumor-Infiltrating Lymphocytes F
 ollowed by Consolidative Oral Cyclophosphamide\, Bevacizumab\, and Pembrol
 izumab\nEstimated primary completion: 1 December 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07720180
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204340-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311203
DTEND;VALUE=DATE:20311204
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07204340)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: TLN-372 in Adva
 nced KRAS Mutant Solid Tumors\nEstimated primary completion: 3 December 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720434
 0
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006650-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06006650)
DESCRIPTION:Pembrolizumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\n
 Study: Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous
  Cell\nEstimated primary completion: 31 December 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06006650
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06078384-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320101
DTEND;VALUE=DATE:20320102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06078384)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Pembrolizumab 
 and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in 
 Resected Early-stage TNBC\nEstimated primary completion: 1 January 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06078384
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689240-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320101
DTEND;VALUE=DATE:20320102
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07689240)
DESCRIPTION:Pembrolizumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Testing
  the Investigational Medication Pembrolizumab After Kidney Removal for Pat
 ients With Non-Clear Cell Renal Cell Carcinoma\nEstimated primary completi
 on: 1 January 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07689240
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Esophageal Squamous Cell Carcinoma.
 \nStudy: Substudy 06E: Umbrella Study of Combination Therapies in Esophage
 al Cancer (MK-3475-06E/KEYMAKER-U06)\nEstimated primary completion: 4 Janu
 ary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6780111
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789082-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320129
DTEND;VALUE=DATE:20320130
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05789082)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study Evaluating the Safety\, Activity\, and Pharmacokinetics of Divara
 sib as a Single Agent or in Combination With Other Anti-Cancer Therapies i
 n Participants With Previously Untreated Advanced or Metastatic Non-Small 
 Cell Lung Cancer With a KRAS G12C Mutation\nEstimated primary completion: 
 29 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05789082
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06770582-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06770582)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing
  the Addition of the Immunotherapy Drug\, Pembrolizumab\, to Radiation The
 rapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy
  for Bladder Cancer\, PARRC Trial\nEstimated primary completion: 1 Februar
 y 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 70582
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06788912)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small
  Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated primary co
 mpletion: 6 February 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK
 -3475) With or Without Chemotherapy When Used With Investigational Agents 
 in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer 
 (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion: 13 Febr
 uary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04165070
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533697-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320218
DTEND;VALUE=DATE:20320219
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05533697)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Study of mRNA
 -4359 Administered Alone and in Combination With Immune Checkpoint Blockad
 e in Participants With Advanced Solid Tumors\nEstimated primary completion
 : 18 February 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05533697
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731907-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06731907)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Pembrolizumab With or Without Chemotherapy in Combination With A
 dditional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3
 475-01G/KEYMAKER U01)\nEstimated primary completion: 12 March 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06731907
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905924-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320330
DTEND;VALUE=DATE:20320331
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT07905924)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: A Study to Eval
 uate the Safety and Effectiveness of Different Doses of RO7836748 Alone or
  in Combination With Other Cancer Therapies in People With Solid Tumors Wi
 th a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutat
 ion\nEstimated primary completion: 30 March 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07905924
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438459-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438459)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Gastric Cancer.\nStudy: GAIA-102 In
 traperitoneal Administration in Patients With Advanced Gastrointestinal Ca
 ncer of Microsatellite Stable With Malignant Ascites\nEstimated primary co
 mpletion: 31 March 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05438459
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486687-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07486687)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Pembrolizumab 
 Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With R
 esidual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy\nEstimat
 ed primary completion: April 2032. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07486687
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422806-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320418
DTEND;VALUE=DATE:20320419
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06422806)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: Measuring if Immunotherapy Plu
 s Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggress
 ive Poorly Differentiated Sarcomas\nEstimated primary completion: 18 April
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0642
 2806
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 nti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimat
 ed primary completion: 30 April 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364631-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320505
DTEND;VALUE=DATE:20320506
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06364631)
DESCRIPTION:Pembrolizumab\, phase 3.\nStudy: CARE1 Pragmatic Clinical Trial
 \nEstimated primary completion: 5 May 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06364631
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952504-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20320524
DTEND;VALUE=DATE:20320525
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06952504)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: A Study t
 o Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizu
 mab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With
  Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GO
 G-3119/ENGOT-en29)\nEstimated primary completion: 24 May 2032. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06952504
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07026474-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07026474)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy 
 for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC\nEstimated pri
 mary completion: December 2032. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07026474
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589804-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20321225
DTEND;VALUE=DATE:20321226
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06589804)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Testing the Addition of Anti-Cancer Drug\, Cetuximab\, to Standa
 rd of Care Treatment (Pembrolizumab) for Returning or Spreading Head and N
 eck Cancer After Previous Treatment\nEstimated primary completion: 25 Dece
 mber 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06589804
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385080-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20321227
DTEND;VALUE=DATE:20321228
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06385080)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: A Study of Amivantamab Alone or in Addition to Other Treatment
  Agents in Participants With Head and Neck Cancer\nEstimated primary compl
 etion: 27 December 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06385080
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06606730-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20330101
DTEND;VALUE=DATE:20330102
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06606730)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Personalizing 
 the Use of Pembrolizumab for Patients Who Have a Strong Response in Early 
 Triple Negative Breast Cancer\nEstimated primary completion: 1 January 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06606730
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929768-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05929768)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: Shorter Chemo-
 Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative 
 Breast Cancer\nEstimated primary completion: 31 March 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05929768
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178730-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07178730)
DESCRIPTION:Pembrolizumab\, phase 3\, Breast Cancer.\nStudy: NeoAdjuvant Th
 erapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy i
 n Clinical Stage II-III\, Triple-negative Early Breast Cancer\nEstimated p
 rimary completion: 31 March 2033. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07178730
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557889-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20330430
DTEND;VALUE=DATE:20330501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06557889)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Reduction in the Number of Chemotherapy Cycles in Combination Wi
 th Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Me
 tastatic Head and Neck Squamous Cell Carcinomas\nEstimated primary complet
 ion: April 2033. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06557889
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755739-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT03755739)
DESCRIPTION:Pembrolizumab\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus C
 hemodrug for Immunotherapy of Advanced Solid Tumors\nEstimated primary com
 pletion: 1 November 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03755739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015853-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07015853)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: ASTRAEA: Reinv
 igorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination My
 eloid Inhibition and Radiation\nEstimated primary completion: December 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07015853
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312137-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20340221
DTEND;VALUE=DATE:20340222
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06312137)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Assess Efficacy and Safety of Pembrolizumab With or Without Saci
 tuzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non S
 mall Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response
  (pCR) (MK-2870-019)\nEstimated primary completion: 21 February 2034. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06312137
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513376-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20340822
DTEND;VALUE=DATE:20340823
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07513376)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizuma
 b Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I
  Non-Small Cell Lung Cancer (V940-014)\nEstimated primary completion: 22 A
 ugust 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07513376
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822373-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20341130
DTEND;VALUE=DATE:20341201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07822373)
DESCRIPTION:Pembrolizumab\, phase 2\, Urothelial Carcinoma.\nStudy: A Phase
  2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pemb
 rolizumab in Patients With Muscle-Invasive Urothelial Cancer\nEstimated pr
 imary completion: November 2034. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07822373
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552181-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20350930
DTEND;VALUE=DATE:20351001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07552181)
DESCRIPTION:Pembrolizumab\, phase 2\, Breast Cancer.\nStudy: Phase II Trial
  of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in P
 atients With Early Stage Triple Negative Breast Cancer\nEstimated primary 
 completion: September 2035. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07552181
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718854-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07718854)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Sacituzumab T
 irumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovaria
 n Clear Cell Cancer\nEstimated primary completion: September 2036. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07718854
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669846-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05669846)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory
  (R/R) PD-L1 Positive NSCLC\nEstimated primary completion: 31 December 203
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05669846
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Pembrolizumab\, phase 2\, Colorectal Cancer.\nStudy: Study to I
 nvestigate Outcome of Individualized Treatment in Patients With Metastatic
  Colorectal Cancer\nEstimated primary completion: 31 December 2038. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: C
 oncurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiat
 ion Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary co
 mpletion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07770100
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05849480-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20400601
DTEND;VALUE=DATE:20400602
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05849480)
DESCRIPTION:Pembrolizumab\, phase 1/2.\nStudy: A Study of CDX-1140\, a CD40
  Agonist\, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Ke
 ytruda in Subjects With Biliary Tract Carcinoma (BTC)\nEstimated primary c
 ompletion: 1 June 2040. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05849480
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04483778-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20401231
DTEND;VALUE=DATE:20410101
SUMMARY:Pembrolizumab: Phase 1 readout est. (NCT04483778)
DESCRIPTION:Pembrolizumab\, phase 1\, Solid Tumors.\nStudy: B7H3 CAR T Cell
  Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young
  Adults\nEstimated primary completion: December 2040. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04483778
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03486873-1973@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20430804
DTEND;VALUE=DATE:20430805
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03486873)
DESCRIPTION:Pembrolizumab\, phase 3\, Solid Tumors.\nStudy: Long-term Safet
 y and Efficacy Extension Study for Participants With Advanced Tumors Who A
 re Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Stu
 dy (MK-3475-587/KEYNOTE-587)\nEstimated primary completion: 4 August 2043.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03486873
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
